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Abstract 
Microbiological assay as one of the most important methods of 
quantification of the antibiotics and determination of the efficacy of 
antibiotics towards test microorganisms was used in this study for the 
assay of the macrolide antibiotics azithromycin, clarithromycin and 
erythromycin in their pharmaceutical dosage forms applying the agar 
diffusion method. Using a strain of Bacillus pumilus ATCC No. 8241 as 
the test organism, azithromycin and clarithromycin at concentrations 
ranging from 1 to 4 µg/ml and erythromycin at concentrations ranging 
from 5 to 20 µg/ml could be measured in capsules and tablets. The 
method was linear (r2 > 0.99), precise, reproducible (coefficient of 
variation less than 10%) and accurate, the content percent of the tested 
drugs was within the pharmacopoeial limit.  The statistical analysis 
showed that there is no significant variation of the assays when the same 
batch was assayed several times within the day and between the days. 
The method was found satisfactory for the assay of the drugs in their 
pharmaceutical dosage forms and successfully applied for assessment of 
an in vitro antibacterial activity of the macrolide antibiotics. 
In addition to the microbiological assay, clarithromycin was 
assayed by the current pharmacopoeial reverse-phase HPLC with UV 
detection at 210 nm and C18 column method. The results obtained by the 
two methods were compared, and according to the statistical analysis of 
the results using the student t-test, there is no significant variation 
between the two methods of assay (probability > 0.05).  
The study developed a method for the assay of azithromycin in its 
pharmaceutical dosage forms using Lambda 2 UV/VIS 
spectrophotometric analysis at 225 nm band. Azithromycin at 
concentrations ranging from 0.25 to 4 mg/ml and it is corresponding 
absorbance were used for calibration curve, and azithromycin samples at 
 iv
concentration of 0.5 mg/ml was measured in capsules. All samples were 
found to be within in the pharmacopoeial limit and the method was linear 
(r2 = 0.9998). When the chemical method was compared with 
microbiological assay statistically using the student t-test, it’s found that 
there was no significant difference between the two methods in the 
determination of azithromycin in its pharmaceutical dosage forms 
(probability > 0.05). 
The study tries to develop HPLC-method for the assay of 
erythromycin stereate tablets, but it’s found very difficult to analyze 
erythromycin stereate tablets by HPLC due to interference of the peaks of 
the erythromycin and the excipients of the formulation. 
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  ﻣﻠﺨﺺ اﻷﻃﺮوﺣﻪ
  
ات اﻟﺤﻴﻮﻳﺔ وﻗﻴﺎس ﻟﺘﺤﻠﻴﻞ اﻟﻜﻤﻰ ﻟﻠﻤﻀﺎداﻟﺘﺤﻠﻴﻞ اﻟﻤﻴﻜﺮوﺑﻰ آﺄﺣﺪ أهﻢ ﻃﺮق ا
 ﺿﺪ اﻟﻤﺎﻳﻜﺮوﺑﺎت اﻷﺧﺘﺒﺎرﻳﺔ أﺳﺘﺨﺪم ﻟﻬﺬﻩ اﻟﺪراﺳﺔ ﻟﺘﺤﻠﻴﻞ اﻟﻤﻀﺎدات اﻟﺤﻴﻮﻳﺔ ﻓﻌﺎﻟﻴﺘﻬﺎ 
ﻣﻦ ﻧﻮع اﻟﻤﺎآﺮوﻟﻴﺪات ﻣﺜﻞ اﻷزﺛﺮوﻣﺎﻳﺴﻴﻦ واﻟﻜﻼرﺛﺮوﻣﺎﻳﺴﻴﻦ واﻹرﺛﺮوﻣﺎﻳﺴﻴﻦ ﻓﻰ 
 اﻟﺒﺎآﺘﺮﻳﺎ ﺑﺈﺳﺘﺨﺪام ﻋﻴﻨﺔ ﻣﻦ. أﺷﻜﺎﻟﻬﺎ اﻟﺼﻴﺪﻻﻧﻴﺔ ﺑﺘﻄﺒﻴﻖ ﻃﺮﻳﻘﺔ اﻹﻧﺘﺸﺎر اﻷﺟﺎرى 
آﻜﺎﺋﻦ إﺧﺘﺒﺎرى ، اﻹزﺛﺮوﻣﺎﻳﺴﻴﻦ ( 1428 CCTAاﻟﺒﻴﻮﻣﻠﺺ )  اﻟﺼﻐﻴﺮة  اﻟﻌﺼﻮﻳﺔ
ﻣﻞ واﻹرﺛﺮوﻣﺎﻳﺴﻴﻦ /  ﻣﺎﻳﻜﺮوﺟﺮام 4  -1واﻟﻜﻼرﺛﺮوﻣﺎﻳﺴﻴﻦ ﻓﻰ ﺗﺮاآﻴﺰ ﺗﺘﺮاوح ﺑﻴﻦ 
ﻣﻞ ﻳﻤﻜﻦ ﻗﻴﺎﺳﻬﺎ ﻓﻰ اﻷﻗﺮاص /  ﻣﺎﻳﻜﺮوﺟﺮام 02-5ﻓﻰ ﺗﺮاآﻴﺰ ﺗﺘﺮاوح ﻣﻦ 
وهﺬﻩ اﻟﻄﺮﻳﻘﺔ دﻗﻴﻘﺔ ( 99.0 < 2r)ﺔ وأﻇﻬﺮت اﻟﻨﺘﻴﺠﺔ ﻋﻼﻗﺔ ﺧﻄﻴ. واﻟﻜﺒﺴﻮﻻت 
اﻟﻨﺴﺒﺔ . وﺻﺤﻴﺤﺔ %( 01ﻣﻌﺎﻣﻞ اﻟﺘﺒﺎﻳﻦ أﻗﻞ ﻣﻦ  )وﺗﻌﻄﻰ ﻧﻔﺲ اﻟﻨﺘﻴﺠﺔ ﻋﻨﺪ ﺗﻜﺮارهﺎ 
اﻟﺘﺤﻠﻴﻞ .  اﻹﺧﺘﺒﺎر آﺎﻧﺖ ﻓﻰ ﺣﺪود دﺳﺘﻮر اﻷدوﻳﺔ  ﺗﺤﺖدوﻳﺔاﻷاﻟﻤﺤﺘﻮاة ﻣﻦ 
اﻹﺣﺼﺎﺋﻰ أﻇﻬﺮ أﻧﻪ ﻻ ﻳﻮﺟﺪ ﺗﺒﺎﺑﻴﻦ واﺿﺢ ﻓﻰ اﻟﻨﺘﺎﺋﺞ ﻋﻨﺪ ﺗﺤﻠﻴﻞ ﻧﻔﺲ اﻟﺪﻓﻌﺔ ﻋﺪة 
اﻟﻄﺮﻳﻘﺔ وﺟﺪت آﺎﻓﻴﺔ ﻟﺘﺤﻠﻴﻞ هﺬﻩ اﻷدوﻳﺔ ﻓﻰ . أﺛﻨﺎء اﻟﻴﻮم أو ﻓﻰ اﻳﺎم ﻣﺨﺘﻠﻔﺔ ﻣﺮات 
أﺷﻜﺎﻟﻬﺎ اﻟﺼﻴﺪﻻﻧﻴﺔ وﻧﺎﺟﺤﺔ ﻋﻨﺪ ﺗﻄﺒﻴﻘﻬﺎ ﻟﺘﺤﺪﻳﺪ ﻓﻌﺎﻟﻴﺔ اﻟﻤﻀﺎدات اﻟﺤﻴﻮﻳﺔ 
  .اﻟﻤﺎآﺮوﻟﻴﺪﻳﺔ  ﻓﻰ اﻟﻮﺳﻂ اﻟﺼﻨﺎﻋﻰ 
ﺑﺎﻹﺿﺎﻓﻪ ﻟﻠﺘﺤﻠﻴﻞ اﻟﻤﺎﻳﻜﺮوﺑﻰ اﻟﻜﻼرﺛﺮوﻣﺎﻳﺴﻴﻦ ﺗﻢ ﺗﺤﻠﻴﻠﻪ ﺑﻮاﺳﻄﺔ اﻟﺘﺤﻠﻴﻞ   
ﺑﺈﺳﺘﺨﺪام اﻷﺷﻌﺔ ﻓﻮق اﻟﺒﻨﻔﺴﺠﻴﺔ آﻜﺎﺷﻒ ﺑﻄﻮل ﻣﻮﺟﺔ ( CLPH) اﻷداء اﻟﻄﺒﻘﻰ ﻓﺎﺋﻖ
اﻟﻨﺘﺎﺋﺞ اﻟﻤﺘﺤﺼﻠﺔ ﻋﻠﻴﻬﺎ  . 81 – ﻧﺎﻧﻮﻣﻴﺘﺮ واﻟﻌﻤﻮد اﻟﻤﺤﺘﻮى ﻋﻠﻰ اﻟﻜﺎرﺑﻮن 012
ﺑﻮاﺳﻄﺔ اﻟﻄﺮﻳﻘﻴﺘﻴﻦ ﺗﻤﺖ ﻣﻘﺎرﻧﺘﻬﺎ وﻃﺒﻘًﺎ ﻟﻠﺘﺤﻠﻴﻞ اﻹﺣﺼﺎﺋﻰ ﻟﻠﻨﺘﺎﺋﺞ ﺑﺈﺳﺘﺨﺪام إﺧﺘﺒﺎر 
اﻹﺣﺘﻤﺎﻟﻴﺔ )ﺿﺢ ﺑﻴﻦ ﻃﺮﻳﻘﺘﻰ اﻟﺘﺤﻠﻴﻞ ﻟﻢ ﻳﻮﺟﺪ ﺗﺒﺎﻳﻦ وا )tset-t tnedutS(  ت–اﻟﻄﺎﻟﺐ 
  (.50.0< 
اﻟﺪراﺳﺔ ﻃﻮرت ﻃﺮﻳﻘﻪ ﻟﺘﺤﻠﻴﻞ اﻷزﺛﺮوﻣﺎﻳﺴﻴﻦ ﻓﻰ ﺷﻜﻠﻪ اﻟﺼﻴﺪﻻﻧﻰ ﺑﺈﺳﺘﺨﺪام   
اﻷزﺛﺮوﻣﺎﻳﺴﻴﻦ ﻓﻰ ﺗﺮاآﻴﺰ .  ﻧﺎﻧﻮﻣﻴﺘﺮ 522 ﺑﺤﺰﻣﺔ 2-اﻟﺘﺤﻠﻴﻞ اﻟﻄﻴﻔﻰ ﻣﻦ ﻧﻮع  ﻻﻣﺪا 
ﻣﻞ وإﻣﺘﺼﺎﺻﻬﺎ اﻟﻤﻘﺎﺑﻞ إﺳﺘﺨﺪﻣﺖ ﻓﻰ ﻣﻨﺤﻨﻰ /   ﻣﻠﺠﺮام 4 – 52.0ﺗﺘﺮاوح ﻣﻦ 
ﻣﻞ  ﺗﻢ ﻗﻴﺎﺳﻬﺎ ﻓﻰ اﻟﻜﺒﺴﻮﻻت /  ﻣﻠﺠﺮام 5.0ﻟﻘﻴﺎس ، وﻋﻴﻨﺎت أزﺛﺮوﻣﺎﺗﻴﺴﻴﻦ ﺑﺘﺮآﻴﺰ ا
  2r)آﻞ اﻟﻌﻴﻨﺎت وﺟﺪت ﻓﻰ ﺣﺪود دﺳﺘﻮر اﻷدوﻳﺔ وآﺎﻧﺖ اﻟﻄﺮﻳﻘﺔ ﺧﻄﻴﺔ . 
ﻋﻨﺪ اﻟﻤﻘﺎرﻧﺔ اﻹﺣﺼﺎﺋﻴﺔ ﻟﻠﻄﺮﻳﻘﺔ اﻟﻜﻴﻤﻴﺎﺋﻴﺔ ﺑﻄﺮﻳﻘﺔ اﻟﺘﺤﻠﻴﻞ اﻟﻤﺎﻳﻜﺮوﺑﻰ ( . 8999.0=
ﻳﻮﺟﺪ ﺗﺒﺎﻳﻦ واﺿﺢ ﺑﻴﻦ اﻟﻄﺮﻳﻘﺘﻴﻦ ﻓﻰ ﻗﻴﺎس  ت ، وﺟﺪ أﻧﻪ ﻻ–ﺑﺈﺳﺘﺨﺪام إﺧﺘﺒﺎر اﻟﻄﺎﻟﺐ 
  ( 50.0< اﻹﺣﺘﻤﺎﻟﻴﺔ )اﻷزﺛﺮوﻣﺎﻳﺴﻴﻦ ﻓﻰ اﻟﺸﻜﻞ اﻟﺼﻴﺪﻻﻧﻰ 
ﻰ ﻋﺎﻟﻰ اﻟﺪﻗﺔ ﻟﺘﺤﻠﻴﻞ ﺔ ﺣﺎوﻟﺖ ﺗﻄﻮﻳﺮ ﻃﺮﻳﻘﺔ ﻟﻠﺘﺤﻠﻴﻞ اﻟﻄﻴﻔاﻟﺪراﺳ  
اﻹرﺛﺮوﻣﺎﻳﺴﻴﻦ أﺳﺘﻴﺮﻳﻴﺖ ﻓﻰ ﺷﻜﻞ اﻗﺮاص وﻟﻜﻦ آﺎﻧﺖ هﻨﺎﻟﻚ ﺻﻌﻮﺑﺔ ﻧﺘﻴﺠﺔ ﻟﺘﺪاﺧﻞ 
  . ﺎﻓﺔ ﻓﻰ ﺗﺮآﻴﺒﺔ اﻟﺤﺒﺔ اﻟﻘﻤﻢ ﻟﻺرﺛﺮوﻣﺎﻳﺴﻴﻦ واﻟﻤﻮاد اﻟﻤﻀ
 
  
 vi
List of Content 
  Content  Page
  Acknowledgement i
  Abstract iii
  Arabic abstract v
  List of content vi
  List of tables x
  List of figures xiii
Chapter one: Introduction and Literature Review 
1- Introduction 1
1.1-  Definition 1
1.1.1- Macrolide Antibiotics 1
1.1.2- Mechanism of action 1
1.1.3-  Spectrum of activity  1
1.1.4- Erythromycin 2
1.1.5- Azithromycin 3
1.1.6- Clarithromycin 4
1.2- Literature Review 5
1..3- Basic Assay Techniques & Principles 34
1.3.1- Biological Testing 34
1.3.2- Principles of agar diffusion 35
1.3.3- The plate assay 35
1.3.4- Factors affecting the assay method 36
1.3.4.1- Reference standard 36
1.3.4.2- Cultures 37
1.3.4.3- Medium 37
1.3.4.4- Kinds of agar assay 37
1.3.4.5- Surface inoculation 37
 vii
1.3.4.6- Heated culture 38
1.3.4.7- Spores 38
1.3.4.8- Incubation temperature 38
1.3.4.9- Dosing 38
1.3.4.10- The sharpness of the zone edge 39
1.3.4.11- The slope of the assay line 40
1.4- Purpose of the study 42
 Chapter two: Materials and methods 
2.1- Materials 43
2.1.1-  Antibiotics 43
2.1.2- Chemicals 44
2.1.3-  Microorganism 44
2.1.4- Culture media 44
2.1.5 - Buffer 45
2.1.6- Instruments 45
2.2-  Methods 45
2.2.1- Microbiological assay 45
2.2.1.1- Condition for assay 45
2.2.1.2-  Preparation of the medium for test organism 46
2.2.1.3-  Preparation of the medium for antibiotic assay 46
2.2.1.4- Preparation of Buffer 46
2.2.1.5-  preparation of inoculum 46
2.2.1.6- Preparation of serial dilutions for standard and 
sample 47
2.2.1.6.1- Preparation of serial dilutions for standard 
Erythromycin 47
2.2.1.6.2-  Preparation of serial dilutions for Erythromycin 
samples 47
 viii
2.2.1.6.3-  Preparation of serial dilutions for standard 
azithromycin and clarithromycin 48
2.2.1.6.4- Preparation of serial dilutions for Azithromycin 
and clarithromycin samples:- 48
2.2.1.7- Procedure 49
  Agar Diffusion Method 49
2.2.2- HPLC method 49
2.2.2.1- Clarithomycin 49
2.2.2.1.1-  Preparation of mobile phase 49
2.2.2.1.2-  Preparation of standard solution 49
 Stock solution 49
 Standard working solutions for calibration curve 50
2.2.2.1.3- Sample preparation 50
2.2.2.1.4- Chromatographic system 50
2.2.2.1.5- Procedure 50
2.2.2.2- Erythromycin 51
2.2.2.2.1- Preparation of the mobile phase 51
2.2.2.2.2- Preparation of the standard solution 51
  Stock solution 51
 Standard solutions for calibration curve 51
2.2.2.2.3- Sample preparation 51
2.2.2.2.4- Chromatographic system 51
2.2.2.2.5- Procedure 52
2.2.3-  Spectrophotometric assay 52
2.2.3.1-  Preparation of serial dilution for standard 
azithromycin Dihydrate 52
2.2.3.2-  Sample preparation 52
2.2.3.3- Assay condition 53
2.2.3.4-  Procedure 53
 ix
2.3 Statistical  analysis 53
3-  Results 54
3.1-  Results of microbiological assay 54
3.2-  Results of HPLC-assay  91
3.3-  Results of spectrophotometric assay  93
3.4- Comparison of microbioogical assay to chemical 
assay 95
4-  Discussion 99
  Conclusion and recommendation 105
  References 106
 x
List of Tables 
  Page
Table-1 Results of microbiological assay of azithromycin 
sample-1 at day-1 55
Table-2 Results of microbiological assay of azithromycin 
sample-1 at day -2 55
Table-3 Results of microbiological assay of azithromycin 
sample-1 at day -3 55
Table-4 Results of microbiological assay of azithromycin 
sample-2 at day -1 56
Table-5 Results of microbiological assay of azithromycin 
sample-2 at day -2 56
Table-6 Results of microbiological assay of azithromycin 
sample-2 at day -3 56
Table-7 Results of microbiological assay of azithromycin 
sample-3 at day -1 57
Table-8 Results of microbiological assay of azithromycin 
sample-3 at day -2 57
Table-9 Results of microbiological assay of azithromycin 
sample-3 at day -3 57
Table-10 Results of microbiological assay of erythromycin 
sample-1 at day -1 58
Table-11 Results of microbiological assay of erythromycin 
sample-1 at day -2 58
Table-12 Results of microbiological assay of erythromycin 
sample-1 at day -3 58
Table-13 Results of microbiological assay of erythromycin 
sample-2 at day -1 
 
59
 xi
Table-14 Results of microbiological assay of erythromycin 
sample-2 at day -2 59
Table-15 Results of microbiological assay of erythromycin 
sample-2 at day -3 59
Table-16 Results of microbiological assay of erythromycin 
sample-3 at day -1 60
Table-17 Results of microbiological assay of erythromycin 
sample-3 at day -2 60
Table-18 Results of microbiological assay of erythromycin 
sample-3 at day -3 60
Table-19 Results of microbiological assay of clarithromycin 
sample-1 at day -1 61
Table-20 Results of microbiological assay of clarithromycin 
sample-1 at day -2 61
Table-21 Results of microbiological assay of clarithromycin 
sample-1 at day -3 61
Table-22 Results of microbiological assay of clarithromycin 
sample-2 at day -1 62
Table-23 Results of microbiological assay of clarithromycin 
sample-2 at day -2 62
Table-24 Results of microbiological assay of clarithromycin 
sample-2 at day -3 62
Table-25 Results of microbiological assay of clarithromycin 
sample-3 at day -1 63
Table-26 Results of microbiological assay of clarithromycin 
sample-3 at day -2 63
Table-27 Results of microbiological assay of clarithromycin 
sample-3 at day -3 63
Table-28 Results of HPLC-assay  (Clarithromycin) 91
 xii
Table-29 Results of spectrophotometric assay (Azithromycin) 
93
Table-30 Comparison : Azithromycin sample-1 95
Table-31 Azithromycin sample-2 95
Table-32 Azithromycin sample-3 95
Table-33 Clarithromycin sample-1 96
Table-34 Clarithromycin sample-2  96
Table-35 Clarithromycin sample-3 96
Table-36 Variations of microbiological assays within the day 97
Table-37 Variations of microbiological assays betweens days 98
 xiii
List of Figures 
  Page
Figure-1 Erythromycin structure 3
Figure-2 Azithromycin structure 4
Figure-3 Clarithromycin structure 5
Figure-4 Microbiological assay of azithromycin sample-1 
(day-1) 
64
Figure-5 Microbiological assay of azithromycin sample-1 
(day-2) 
65
Figure-6 Microbiological assay of azithromycin sample-1 
(day-3) 
66
Figure-7 Microbiological assay of azithromycin sample-2 
(day-1) 
67
Figure-8 Microbiological assay of azithromycin sample-2 
(day-2) 
68
Figure-9 Microbiological assay of azithromycin sample-2 
(day-3) 
69
Figure-10 Microbiological assay of azithromycin sample-3 
(day-1) 
70
Figure-11 Microbiological assay of azithromycin sample-3 
(day-2) 
71
Figure-12 Microbiological assay of azithromycin sample-3 
(day-3) 
72
Figure-13 Microbiological assay of erythromycin sample-1 
(day-1) 
73
Figure-14 Microbiological assay of erythromycin sample-1 
(day-2) 
74
Figure-15 Microbiological assay of erythromycin sample-1 
(day-3) 
75
 xiv
Figure-16 Microbiological assay of erythromycin sample-2 
(day-1) 
76
Figure-17 Microbiological assay of erythromycin sample-2 
(day-2) 
77
Figure-18 Microbiological assay of erythromycin sample-2 
(day-3) 
78
Figure-19 Microbiological assay of erythromycin sample-3 
(day-1) 
79
Figure-20 Microbiological assay of erythromycin sample-3 
(day-2) 
80
Figure-21 Microbiological assay of erythromycin sample-3 
(day-3) 
81
Figure-22 Microbiological assay of claithromycin sample-1 
(day-1) 
82
Figure-23 Microbiological assay of claithromycin sample-1 
(day-2) 
83
Figure-24 Microbiological assay of claithromycin sample-1 
(day-3) 
84
Figure-25 Microbiological assay of claithromycin sample-2 
(day-1) 
85
Figure-26 Microbiological assay of claithromycin sample-2 
(day-2) 
86
Figure-27 Microbiological assay of claithromycin sample-2 
(day-3) 
87
Figure-28 Microbiological assay of claithromycin sample-3 
(day-1) 
88
Figure-29 Microbiological assay of claithromycin sample-3 
(day-2) 89
 xv
Figure-30 Microbiological assay of claithromycin sample-3 
(day-3) 
90
Figure 31 Calibration curve of claithromycin (HPLC) method 92
Figure 32 Calibration curve of azithromycin 
(Spectrophotometric) method 
94
 
 1
1- Introduction 
1.1 Definition 
1.1.1 Macrolide Antibiotics: 
Macrolide antibiotics are produced by Streptomyces species and 
they are used primarily against gram-positive bacteria. They are 
characterized by four common characteristics (a) a large lactone ring 
hence the name macrolide, (b) a ketone group, (c) a glycosidically linked 
amino sugar. (d) diethylamino moiety on the sugar residue which 
explains the basicity of these antibiotics (pka values are between 6-9) and 
affords the possibility of preparing their clinical useful salts. (Delgado, et 
al., 1998)  
Macrolides consist of a 12 to 16 membered Ketolide ring, to which 
one or more sugar moieties are substituted. This class of antibiotics has 
been widely used in human and food producing animals. Because of 
extensive worldwide use clinically for human and veterinary, macrolide 
antibiotics are expected to be widely distributed in biological and 
environmental samples. Antibiotics released into the environment are of 
concern because they have potential to accelerate development of 
antibiotic resistance by gene transfer to human. (Potera C. 2001)  
1.1.2 Mechanism of action: 
Macrolide antibiotics bind selectively to a specific site on the 50s 
ribosomal subunit to prevent the translocation step of bacterial protein 
synthesis. It does not bind to mammalian ribosome’s (Wilhelm, et al., 
1967)  
1.1.3 Spectrum of activity    
The spectrum of antibacterial activity of the more potent 
macrolides, such as erythromycin, resembles that of penicillin. They are 
frequently active against bacterial strains that are resistant to the 
penicillin. The macrolides are generally effective against most species of 
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gram-positive bacteria, both cocci and bacilli and exhibit useful 
effectiveness against gram-negative cocci, especially Neisseria species. 
Many of macrolides are also effective against Treponema palidium. In 
contrast to penicillin, macrolides are also effective against Mycoplasma, 
Chlamydia,Compylobacter, and Legionella species. Their activity against 
most species of gram-negative bacilli is generally low and often 
unpredictable, though some strains of H. influenzae and Brucella species 
are sensitive. (Wilhelm, et al., 1967)    
  Commercially available macrolide antibiotics chosen for this study 
are Erythomycin, Azithromycin and Clarithromycin. 
1.1.4 Erythromycin: 
Erythromycin is a mcrolide antibiotic that is produced by the 
Actinomycete species, Streptomyces erythreus. Erythromycin is a 
polyhydroxylactone that contains two sugars. The aglycone portion of the 
molecule, erythranolide , is a 14-membered lactone ring. An amino sugar, 
D-desosamine, is attached through a B-glycosidic linkage to the C-5 
position of the lactone ring. The tertiary amine of desosamine confers a 
basic character to erythromycin (pka 8.8). Through this group, a number 
of acid salts of the antibiotic have been prepared. A second sugar, L-
caldinose, which is unique to erythromycin, is attached via a B-glycosidic 
linkage to the C-3 position of the lactone ring. (Omura S. 1984)  
Erythromycin achieved rapid early acceptance as a well-tolerated 
antibiotic of value for the treatment of a variety of upper respiratory and 
soft tissue infections caused by gram-positive bacteria. It is also effective 
against many venereal diseases, including gonorrhea and syphilis, and 
provides a useful alternative for the treatment of many infections in 
patients allergic to penicillins. Erythromycin has been shown to be an 
effective therapy for Eaton agent Pneumonia (Mycoplasma pneumoniae), 
venereal disease caused by Clamydiae, bacterial enteritis caused by 
Compylobacter jejuni, and Legunnaire’s disease. (Wilhelm, et al., 1967). 
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Figure-1: Erythromycin structure 
1.1.5 Azithromycin: 
Azithromycin is azalide antibacterial semisynthetic acid stable 
erythromycin derivative with an expanded spectrum of activity and 
improved tissue pharmacokinetic characteristic relative to erythromycin. 
Azithromycin is absorbed rapidly and distributes widely throughout the 
body except cerebrospinal fluid. Its unique pharmacokinetic properties 
include extensive tissue distribution and high drug concentration within 
cells (including phagocytes). These attributes result in much greater tissue 
or secretion drug concentrations compared to simultaneous serum 
concentrations. The terminal elimination half life was reported to be 68 hr 
and it’s prolonged because of extensive tissue sequestration and binding. 
(Christopher, et al., 1996) 
The spectrum of antimicrobial activity of azithromycin is similar to 
that observed for erythromycin and clarithromycin but with some 
interesting differences. In general it is more active against gram-negative 
bacteria and less active against gram-positive bacteria than its close 
relatives. The greater activity of azithromycin against H. influenzae, Mor. 
catarrhalis, and Myc. pneumoniae coupled whith its extended half-life 
permits a 3-day dosing schedule for the treatment of respiratory tract 
infections caused by these pathogens. The clinical efficacy of 
azithromycin in the treatment of urogenital and other sexually transmitted 
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infections caused by Chlamydia trachomatis, N. gonorrhoeae, 
Haemophilus ducreyi and Ureaplasma urealytiecum suggests that single-
dose therapy with the antibiotic for uncomplicated urethritis or cervicitis 
may have advantages over other antibiotics. (Wilhelm, et al., 1967)  
 
Figure-2 : Azithromycin structure 
1.1.6- Clarithromycin: 
Clarithromycin is 6-methyl ether erythromycin. The simple 
methylation of the 6-hydroxyl group of erythromycin creates a 
semisynthetic derivative that fully retains the antibacterial properties of 
the parent antibiotic, while markedly increasing acid stability and oral 
bioavailability and reducing gastrointestinal side effects associated with 
erythromycin. (Strurgil, et al., 1992 )   
Some of the microbiologic properties of clarithromycin also appear 
to be superior to those of erythromycin. It exhibits greater potency against 
Myc. pneumoniae, Legionella species. Chlamydia pneumoniae, H. 
influenzae, and Mor. catarrhalis  than does erythromycin. Also of interest 
is the activity of clarithromycin against unusual pathogens such as 
Borrelia burgdorferi, the cause of Lyme disease, and the Mycobacterium 
avium complex (MAC). Clarithromycin is significantly more active than 
erythromycin against group A streptococci, Streptococcus pneumoniae 
and the viridans group of streptococci in vivo because of its superior oral 
bioavailability. However, the greater cost of clarithromycin compared 
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with erythromycin must be weighed against it’s potentially greater 
effectiveness. (Wilhelm, et al., 1967)  
 
Figure-3: Clarithromycin structure 
 
1.2-Literature Review 
 
 Biological assays have been introduced to determine the 
concentration of a single type of macrolide using erythromycin – 
sensitive  strains as indicators. (Riedel et al., 1992) (Assaf, et al., 1999)  
This method is routinely used for the determination of the efficacy 
of antibiotics towards test microorganisms. The biological activities of 
antibiotics are semi- quantitatively measured, typically using two fold 
serial dilutions of drug concentrations in microtiter plates. Although it is 
convenient for the estimation of effective drug concentrations by logic 
analysis, it is difficult to distinguish activities of individual drugs in 
mixtures showing synergistic effects. (Eguchi, et al., 2004)  
 Most drawbacks arise from test accuracy and precision, because the 
bioassay is largely dependent on culture techniques (e.g. liquid culture 
and plate culture) and the physiological state of indicator microorganism. 
(Yong-Hak Kim, et al., 2005)  
 But the bioassay remains the only method that resolves doubt with 
respect to possible loss of activity in which a reduction in antimicrobial 
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activity reveals subtle changes not demonstrated by chemical methods. 
(USP-28-2005)  
Recently, the increase in the number of antibiotics increased the 
importance of their assay for quality control. Though physicochemical 
methods for assay in some cases are enough, in many cases 
microbiological assay remains the only method for measuring the potency 
of antibiotics. Microbiological assay technique can be carried out without 
the expensive sophisticated equipment. Poor reproducibility and 
insufficient designs in microbiological assay is attributed to “biological 
error”. Statistical evaluation as normally applied to simple individual 
assays gives an idea of the limitation imposed by technique and assay 
design. It does not take into account the gross error or bias which can 
arise from neglect of the special features of assay method and the 
principle of quantitative analysis. Thus, evaluation of precision is no 
substitute for painstaking efforts to control physical conditions and 
operating procedures so as to obtain an accurate estimate of potency. 
(Hewitt, 1977) 
It is very necessary to quantify antibiotics because in some cases 
the margin between sub dose (ineffective) and overdose (toxic) may be 
small. Even if the overdose is not toxic in some cases, it is not accepted 
on economic bases. (Hewitt, 1977). 
Antibiotic-microbial assays are used to determine the amount of 
erythromycin in pharmaceutical formulations (USP-28-2005), and 
similarly used also to determine the amount of azithromycin and 
clarithromycin in pharmaceutical formulations (Pharmacopoeia of China, 
2000)  
The validation of a microbiological assay, applying the cylinder 
plate method, for the determination of the antibiotic azithromycin was 
described using a strain of Micrococcus luteus ATCC 9341 as the test 
organism. Azithromycin at concentrations ranging from 0.1 to 0.4 µg/ml 
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could be measured in capsules and suspensions. A prospective validation 
of the method showed that it was linear (r=0.998), precise ( RSD = 1.4 – 
capsules, RSD = 1.19 – powder for suspension and RSD = 1.73- oral 
suspensions) and  accurate (it measured the added quantities). The study 
concluded that the microbiological assay is satisfactory for quantification 
of in vitro antibacterial activity of azithromycin. (Breier et al., 2002)  
The study of pharmacokinetics of azithromycin and penetration to 
peripheral human lymph was carried out in 14 healthy male volunteers 
taking 1 g orally after overnight fasting. Samples were analyzed by 
microbiological assay. The mean peak concentrations were 0.82 +/- 0.23 
mg/l after 1.7 +/- 0.5 h in serum and 0.22 +/- 0.07 mg/l after 3.1 h in 
lymph. Nine of the 14 subjects showed a second and lower serum peak 
indicating the existence of enterohepatic circulation. The total areas under 
the serum concentrations curves (AUCs) till infinity were 7.9 +/- 3.1 mg. 
h/l compared to 4.4 +/- 1.2 mg.h/l in lymph. The mean lymph AUC was 
68.1 +/- 20.7% of the serum AUC indicating a penetration ratio of 0.68. 
However, the actual amounts penetrating the tissues were much higher 
than this ratio suggests. Thus, after 6 h 81% of the drug was within the 
tissue compartment and after 120 h, 63% of the azithromycin was still 
present in the tissue compartment. The urinary recovery of azithromycin 
was 14.7 +/- 7.7% during the first 48 h. The serum curves and lymph 
curves displayed a distinctly slower phase of elimination after 12 h. The 
mean serum half-life was 5.4 +/- 3.4 h during the first 12 h, whereas the 
value was 44.2 +/- 10.1 h during the interval 12-120 h. The corresponding 
half-life values for the peripheral lymph were 5.4 +/- 2.2 h and 50.8 +/- 
11.6 h. Azithromycin possesses key pharmacokinetic properties that are 
prerequisites for a convenient once-daily dosage schedule which may 
improve patient compliance. (Bergan T et al., 1992) 
A comparative distribution of Azithromycin in lung tissue of 
patients given oral daily dose of 500 and 1000mg was carried by 
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microbiological assay. Samples were collected from plasma, lung tissue 
and bronchial washing during open chest surgery, and assayed by 
microbiological assay. It has been found that azithromycin was widely 
distributed within the lower respiratory tract and sustained levels of the 
drug were detectable at last sampling time in lung tissue, doubling the 
dose of the antibiotic resulted in a proportional increase in lung area 
under the curve and peak tissue concentration. It has been found that also 
the pharmacodynamic parameter AUC/MIC for susceptible and 
intermediate strains of Streptococcus pneumoniae increased after 
administration of the 1000 mg schedule compared with 500 mg in 
pulmonary tissue. The study concluded that lung exposure to 
azithromycin is increased proportionally by doubling the dose, which 
results in a predictable pharmacokinetic behavior of the drug in the lower 
respiratory tract.  (Romano et al., 2003) 
Pharmacokinetics of azithromycin and its concentration in body 
fluids and bronchoalveolar lavage cells in foals was determined by 
microbiological assay, and from measurement of azithromycin 
concentrations in serum, peritoneal fluid, synovial fluid, pulmonary 
epithelial lining fluid and bronchoalveolar cells the half-life of 
azithromycin was found to be 20.3 hours, body clearance was 
10.4ml/min.kg, and apparrent volume of distribution of steady state was 
18.6L/kg. (Stephanie et al., 2001)  
The validation of a simple, sensitive and specific agar diffusion 
bioassay, applying cylinder-plate method, for the determination of the 
antibiotic azithromycin in ophthalmic solutions was described. Using a 
strain of Bacillus subtilis ATCC 9372 as the test organism, azithromycin 
at concentrations ranging from 50.0 to 200.0 µg/ml could be measured in 
ophthalmic solutions. A prospective validation of the method showed that 
the method was linear (r = 0. 999 9) and precise (RSD = 0. 70) and 
accurate (it measured the added quantities). The results obtained by 
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bioassay method could be statistically calculated by linear parallel model 
and by means of regression analysis and verified using analysis of 
variance (ANOVA). The study concluded that the microbiological assay 
is satisfactory for quantification of azithromycin in ophthalmic solutions. 
(Salgado HR, Roncari AF., 2005)  
The pharmacokinetics of azithromycin was determined over a 192-
h period following oral administration of a single 500-mg dose to six 
healthy volunteers and to 16 cirrhotic patients (ten class A and six class 
B; Pugh's classification). Plasma and urinary levels were determined by 
microbiological assay. The mean Cmax, obtained 2-3 h after 
administration, was 0.29 mg/L in volunteers, and 0.39 and 0.51 mg/L in 
class A and class B cirrhosis, respectively. The elimination half-life was 
53.5 h in control subjects, and 60.6 and 68.1 h in class A and class B 
cirrhotic patients, respectively. The mean residence time was significantly 
higher in class B patients, but AUC, Vd, Cltot and Clr values appeared to 
be similar in all groups. The mean urinary recovery of azithromycin at 
192 h varied from 11-15.7%, and did not differ significantly among 
groups. These results demonstrate that azithromycin pharmacokinetics do 
not differ consistently in patients with mild or moderate hepatic 
impairment in comparison with healthy volunteers. Therefore, no dosage 
modifications of azithromycin seem to be required for patients with class 
A or B liver cirrhosis. (Mazzei T et al., 1993) 
 The disposition kinetics and plasma availability of erythromycin in 
broiler chickens after single intravenous (i.v.), intramuscular (i.m.), 
subcutaneous (s.c.) and oral administrations (p.o.) of 30 mg kg(-1) b. wt.  
were investigated. Tissue residue profiles were also studied after multiple 
intramuscular, subcutaneous, and oral administration of 30 mg kg(-1) b. 
wt., twice daily for three consecutive days. Plasma and tissue 
concentrations of erythromycin were determined using microbiological 
assay methods with Micrococcus luteus as the test organism. Following 
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intravenous injection, plasma concentration-vs-time curves were best 
described by a two compartment open model. The decline in plasma drug 
concentration was bi-exponential with half-lives of (t(1/2alpha)) 0.19 h 
and (t(1/2beta)) 5.3 h for distribution and elimination phases, 
respectively. After intramuscular, subcutaneous and oral administration 
erythromycin at the same dose was detected in plasma at 10 min and 
reached its minimum level 8 h post-administration. The peak plasma 
concentration (Cmax) were 5.0, 5.3, and 6.9 microg x ml(-1) and were 
attained at 1.7, 1.4, and 1.3 h (Tmax), respectively. The elimination half-
lives (T(1/2el)) were 3.9, 2.6, and 4.1 h and the mean residence times 
(MRT) were 3.5, 3.2, and 3.6 h, respectively. The systemic 
bioavailabilities were 92.5, 68.8, and 109.3%, respectively. In vitro 
protein binding percent of erythromycin in broiler plasma ranged from 21 
to 31%. The limit of quantification (LOQ) for the assay was 0.03 microg 
x ml(-1) in plasma and tissues. The tissue level concentrations were 
highest in the liver, and decreased in the following order: plasma > 
kidney > lung > muscle and heart. No erythromycin residues were 
detected in tissues and plasma after 24 h except in liver and kidney where 
it persisted during 48 h following intramuscular and oral administrations. 
(Goudah A et al., 2004) 
Erythromycin ethylsuccinate in plasma was assayed by 
microbiological method. A 500 mg of the antibiotic was given to nine 
healthy volunteers, four males and five females with water or with an 
alcoholic beverage. When given with alcohol, the antibiotic has got a 
longer lag time and smaller area under curve (ANC). A conclusion had 
been reached that ethyl alcohol consumption is responsible for the 
delayed absorption of erythromycin. Alcohol affects gastric emptying. 
(Morasso et al., 1990) 
The validation of an analytical method for quantitative 
determination of erythromycin thiocyanate in an antibiotic preparation for 
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veterinary use was carried out. This method is based on the 
microbiological method described in European Pharmacopoeia to analyze 
erythromycin thiocyanate as a raw material. This erythromycin 
thiocyanate preparation is presented as powder for oral administration 
after mixing with feed. For that reason, it was planned to validate the 
method for the quantitative determination of erythromycin thiocyanate 
incorporated both in the medical premix and the mixture with feed. The 
microbiological method followed a liner model and was not proportional. 
The number of replicates needed to obtain a valid result was less than 
four in all cases. The small difference in concentration expressed in 
natural logarithm detected by the method, was 0.1. From the results, it 
can be concluded that the proposed microbiological method was valid and 
suitable for the quantitative determination of erythromycin thiocyanate in 
medicated premix and in mixture with feed. (Bernabelu et al., 1999)  
Microbiological method was developed to quantitate erythromycin 
(ERY) and tylosin (TYL) in animal feeds in the presence of 11 other 
drugs: 3 nitrofurans, 2 tetracycline antibiotics, 3 sulfonamides, 2 
coccidiostats, and 1 antibacterial growth promoter. ERY and TYL were 
separated from coexisting drugs, detected by thin-layer chromatography, 
and quantitated microbiologically by an agar diffusion method. Analysis 
of 125 experimental animal feed samples fortified at 5 levels (7.5-400 
ppm) with ERY and TYL and at 1 level (50 ppm) with the rest of the 
drugs gave limits of quantification of 2 and 5 ppm, recoveries of 90.3 and 
92.4%, and relative standard deviations of 4.3-7.3% and 3.6-6.1%, 
respectively. (Markakis PK., 1996) 
Microbial receptor competitive binding assay was used for 
determining the macrolide content in various matrices, human serum, 
urine, tissue homogenate samples, specimens of grain and premixed feed. 
The method was sensitive, class-specific and precise, and the 
recommended screening concentrations for specimens of the serum, 
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urine, tissue and grains were 200, 200, 100 and 1 200 ng/g (ng/ml), 
respectively, with a relative standard deviation less than 8%. Microbial 
receptor competitive binding assay was found to be accurate and rapid for 
efficient qualitative and quantitative assay of the total macrolide content 
in various matrices. (Qin Y et al., 2004) 
Spectrofluorimetric analysis was used for determination of 
macrolide antibiotics in bulk and pharmaceutical formulations. The 
method is based on the oxidation by cerium (VI) in the presence of 
sulphuric acid and monitoring the fluorescence of cerium (111) formed at 
λex 255 nm and λem 348 nm. All variables affecting the reaction conditions 
as cerium (VI), sulphuric acid concentrations, heating time, temperature 
and dilution solvents were carefully studied and linear calibration graphs 
were obtained in the range of 42.6-1200 ng ml-1 with a percentage relative 
standard deviation in the range 0.014-0.058%. Quantification and 
detection limits were calculated. The method was applied successfully for 
the assay of the studied drugs in pure and pharmaceutical dosage forms as 
tablets, capsules and suspension. Recovery experiments revealed 
recovery of 98.3-100.8%.  The effect of potential interference due to 
common ingredients as glucose, lactose, citric acid, and propylene glycol 
was investigated. Applying standard addition method shows a recovery of 
97.7-100.9% macrolide antibiotics from their corresponding dosage 
forms. (Pakinaz et al., 2002)  
Recent liquid chromatography-tandem mass spectrometry methods 
using different mass spectrometers (ion-trap, triple-quadruple and time-
of-flight) were used for the determination of macrolides and other 
antimicrobials in the environment (water, sediment and soil). Limits of 
detection as low as 2 ng/l can be achieved. Studies show that 
antimicrobials are present in the aquatic environment at concentrations 
with maxima ranging from 6 ng/l of sulfamethizole in surface water to 
12 mg/l of chlortetracycline in animal wastewaters. Effluents from 
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wastewater- and sewage-treatment plants have received most attention 
because of the evidence that their removal of such compounds has been 
unsuccessful. (Silvia et al., 2005) 
Single analyte HPLC methods and multianalyte HPLC methods 
were used for the analysis of macrolide antibiotics at a low concentration 
level, i.e. pharmacokinetic studies and residue analysis. Both of these 
areas involve the treatment of biological and foodstuff matrices, 
respectively. Single analyte HPLC methods used were; 
Spectrophotometric (UV, DAD) and fluorescence based methods, mass 
spectrometry methods and electrochemical methods (amperometric and 
coulometric).While multianalyte HPLC methods used were 
electrochemical methods (amperometric and coulometric) and mass 
spectrometry methods. The study concluded that the reversed phase is the 
preferred elution mode for this family of antibiotics using, in most cases, 
C18 or C8 columns. Liquid–liquid extraction with organic solvents, 
mainly with tert-methylbuthylether has been demonstrated to provide 
clean extracts from biological samples, but it is also possible to perform a 
simpler sample preparation by dilution or filtration of the samples 
whenever the target concentrations are not too low, as it can be the case 
for urine samples for example. On the other hand when the analysis 
should be performed at the lowest values, i.e. residue analyses mainly in 
food matrices, further clean-up with solid phase extraction cartridges has 
been proven to be the most suitable approach. Despite the undoubted 
advantages of using mass spectrometry detection, macrolides can also be 
analyzed at low concentration levels with other kinds of detectors, with or 
without prior derivatisation of the analytes, which may constitute 
powerful and cost-effective alternatives, in particular when only 
screening and/or post-screening are needed. (Gonza lez et al., 2005) 
A validated, highly sensitive and precise high-performance liquid 
chromatographic (HPLC) method for the determination of the macrolides 
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erythromycin, azithromycin, clarithromycin and roxithromycin in human 
serum was described. A diethyl ether extract, obtained from serum using 
a saturated sodium carbonate solution, was treated with 9-
fluorenylmethyloxycarbonyl chloride (FMOC–Cl) for 40 min at 40°C and 
chromatographed on a base-deactivated octadecyl column, maintained at 
50°C during elution, using an eluent composed of acetonitrile–hydrogen 
phosphate buffer, pH 7.5, with 0.125% triethylamine (3:2, v/v). 
Fluorescence detection was used at an excitation wavelength of 255 nm 
and an emission wavelength of 315 nm. Erythromycin, clarithromycin, 
roxithromycin and azithromycin were found to have retention times of 
8.8, 15.7, 17.1 and 20.7 min, respectively. Recoveries ranging from 93 to 
104% were found with reproducibility coefficients of variation of 1.1–
5%. Mean correlation coefficients of 0.9997, 0.9998, 0.9996 and 0.9994 
were found for the linear calibration curves (n=2) of erythromycin 
(0.320–16.1 mg/l), roxithromycin (3.24–19.4 mg/l), clarithromycin 
(0.190–19.4 mg/l) and azithromycin (0.0988–4.94 mg/l), respectively. 
(Sastre Toraño.J and Guchelaar H.-J., 1998) 
A disposable electrochemical enzyme-linked immunosorbent assay 
(ELISA) for the detection of two macrolides (erythromycin and tylosin) 
in bovine muscle was developed using a screen printed electrode (SPE) 
system as a differential pulse voltammetry (DPV) transducer with mouse 
anti-erythromycin (and anti-tylosin) monoclonal antibodies (MAb) 
serving as molecular recognition elements. The immunochemical system 
makes use of the competition assay principle, and employs an 
erythromycin (or tylosin)-BSA conjugate as coating molecule. After 
competition between free and coated analyte for the antibodies, the 
activity of the alkaline phosphatase labelled antiglobulins was measured 
electrochemically using 1-naphthylphosphate as substrate. Using standard 
solutions of erythromycin and tylosin, the detection limit of the assay was 
0.2 ng/ml determined to be for erythromycin and 2.0 ng/ml for tylosin, 
 15
while the sensitivity (25% inhibition concentration) was 1.0 ng/ml for 
erythromycin and 3.0 ng/ml for tylosin. The suitability of the assay for 
quantification of erythromycin and tylosin in bovine muscle was also 
studied. Spiked and real samples were analysed using the immunosensor 
system developed in the study. The ELISA showed precision values 
(relative standard deviation, RSD%) ranging from 4 to 9% for 
erythromycin and from 8 to 15% for tylosin; the accuracy (relative error, 
RE%) ranged from -11 to 6% and from -4 to 12% for erythromycin and 
tylosin, respectively. Results obtained on real samples were confirmed by 
micro-liquid chromatography coupled on line with tandem mass 
spectrometry (micro-LC-MS-MS), using an atmospheric pressure 
ionisation (API) source and an ionspray (IS) interface. The latter provides 
unequivocal identification and quantification of the analytes at the level 
of interest. (Ammida NH et al., 2003) 
Voltammetric investigation of macrolides by an HPLC-coulometric 
assay was done using a dual electrode cell in combination with a high- 
throughput LC method. The half-wave potentials (E (½)) of the 
macrolides investigated ranged from 0.734 to 0.866 v, and the current 
responses reached the maxima at over 1.0 v. The current response of the 
downstream electrode displayed a non-linear behavior at high potentials 
over + 0.75 v. probably because of polarization of solvent components e.g 
water. The HPLC-coulometric assay was optimized with the potentials of 
the upstream for detection of 14- and 15- membered macrolides 
(sensitivity < 0.05 mugmL(-1)) but not for a 16 membered macrolide, 
tylosine (sensitivity . 0.1 mugmL (-0)). The assay shows interferences 
from biometrics in rat’s blood, plasma and serum, and human urine, but 
they were effectively removed by a cold acetonitrile extraction method. 
(Yong-Hak Kim et al., 2005)   
 The application of various thin-layer chromatography, paper 
chromatography, gas chromatography, high performance liquid 
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chromatography and capillary zone electrophoresis procedure, with 
various detection methods such as, bioautography, UV 
spectrophotometry, fluorometry, eletrochemical detection, 
chemiluminescence and mas spectrometry techniques were used for 
analysis of most macrolide antibiotics such as erythromycin and its 
related substances, azithromycin claritromycin,…etc. These techniques 
have been applied to the separation and quantitative analysis of the 
macrolides in formulation media, purity assessment of raw materials, 
assay of pharmaceutical dosage forms and the measurement of clinically 
useful macrolide antibiotics in biological samples such as blood, plasma, 
serum, urine and tissues. (Isadore et al., 1998)  
A liquid chromatography–mass spectrometry method was proposed 
for the determination of seven macrolides authorised in the EU as 
veterinary drugs for food-producing animals. Sample treatment involves 
extraction of the analytes with a water–methanol mixture containing 
metaphosphoric acid and clean-up by SPE with a cation-exchange 
cartridge. Separation was carried out in an end-capped silica-based C18 
column and mobile phases consisting of water/acetonitrile mixtures 
containing trifluoroacetic acid. A gradient elution, from 28 to 40% 
acetonitrile was used. Detection was performed by mass spectrometry 
with electrospray ionisation in the positive mode. Several parameters 
affecting the mass spectra were studied. The protonated molecular ion 
was selected for quantification purposes under selected ion monitoring 
mode. Detection limits were in the range 1–20 µg l−1. Recoveries ranged 
between 56 and 93% with RSD lower than 12%. The method has been 
successfully applied for multiresidue determination of seven macrolides 
below the MRLs established by the European Union. (Rosa Codony et 
al., 2002) 
Liquid chromatography coupled to mass spectrometry, with a 
particular emphasis on tandem mass spectrometry and the new criteria 
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established by the European Union was used for performing confirmatory 
analysis of macrolides and other veterinary drugs in animal-food 
products. The combination of liquid chromatography and tandem mass 
spectrometry allows unequivocal identification of traces of antibiotics and 
antibacterial agents in complex biological matrices, such as honey, eggs, 
milk and meat. The sensitivity of the coupling is particularly useful for 
confirming the presence of banned substances that require limits of 
detection as low as possible. (Gentili et al., 2005) 
A liquid chromatography–mass spectrometry (LC–MS) method 
was developed for the determination of five macrolides in natural water 
samples,using kitasamycin as surrogate. The macrolides were extracted 
from water samples using Oasis HLB cartridges. Pre-concentration 
factors up to 250 were obtained. Separation was carried out in an end-
capped silica-based C18 column and mobile phases consisting of 
water/acetonitrile mixtures containing ammonium acetate. Detection was 
performed by mass spectrometry with a single quadruple and a triple 
quadruple using an electrospray interface. The quality parameters 
obtained with these two approaches were compared. The detection limits 
of the whole process were about 1 ng l−1. The recoveries from 250 ml of 
water samples spiked at 25–125 ng l−1 level were in the range of 85–
115%, except for azithromycin levels, which were around 70%. 
Erythromycin-H2O, clarithromycin and azithromyzin were found, at the 
sub ng l−1 level, in the studied rivers. (So nia Abuin et al., 2006) 
A method using liquid chromatography electrospray ionization 
tandem mass spectrometry (LC/ESI-MS/MS) for the determination of 
trace levels of five macrolide antibiotics (spiramycin, tilmicosin, 
oleandomycin, erythromycin, and tylosin) in eggs was presented. Data 
acquisition under MS/MS was achieved by applying multiple reaction 
monitoring (MRM) of two or three fragment ion transitions to provide a 
high degree of sensitivity and specificity for both quantification and 
 18
confirmation. Matrix-matched standard calibration curves were used to 
achieve the best accuracy of the method. A fully nested experimental 
design was used to study the measurement uncertainty arising from 
intermediate precision and trueness or proportional bias. The overall 
recoveries, that is, those determined by the nested experiments, of 
spiramycin, tilmicosin, oleandomycin, erythromycin, and tylosin at 
fortified levels of 60, 100, 200, and 300 microg/kg were 96.8, 98.2, 98.3, 
98.8, and 95.4%, respectively. The LC/ESI-MS/MS method detection 
limits (S/N > or = 3:1) of five macrolides were <1.0 microg/kg. (Wang J. 
et al., 2005) 
Macrolide antibiotics and other Pharmaceutical residues were 
determined by low concentrations found in aqueous and solid 
environmental samples, using liquid chromatography–tandem mass 
spectrometry (LC–MS/MS). Advanced aspects of current LC–MS/MS 
methodology, including sample preparation and matrix effects, were 
discussed. The method was found sensitive and accurate to detect the low 
concentrations of the tested pharmaceuticals in environmental samples. 
(Mira Petrović et al., 2005) 
A simple and reliable method using liquid chromatography–
electrospray ionization-mass spectrometry (LC–ESI-MS) has been 
developed for the determination of macrolide antibiotics, erythromycin 
(EM), oleandomycin (OM), kitasamycin (KT), josamycin (JM), 
mirosamicin (MRM), spiramycin (SPM), tilmicosin (TLM) and tylosin 
(TS) in meat and fish. The LC separation was performed on a TSKgel 
Super ODS column (100 mm×2 mm i.d.) with a gradient system of 0.2% 
acetic acid–acetonitrile (containing 0.2% acetic acid) as the mobile phase 
at the flow rate of 0.2 ml/min. The positive ionization produced the 
molecular related ions, (M+2H)2+, at m/z 422 and 435 for SPM and TLM, 
and (M+H)+, at 734, 688, 772, 828, 728 and 916 for EM, OM, KT, JM, 
MRM and TS, respectively. The calibration graphs for each drug were 
 19
rectilinear from 0.05 to 25 µg with selected ion monitoring (SIM). The 
drugs were extracted with 0.2% metaphosphoric acid–methanol (6:4), and 
the extracts were cleaned up on an Oasis HLB cartridge (60 mg). The 
recoveries of the drugs from meat and fish fortified at the 0.2 µg/g level 
was 70.4–93.2% with high precision. The limits of quantification of the 
drugs in meat and fish were 0.01 µg/g. (Masakazu Horie et al., 2003) 
A LC method with UV detection for determining azithromycin 
impurities in tablets as pharmaceutical form has been developed. It is to 
be employed in routine and stability tests. A linear gradient elution was 
employed starting with 47% A and 53% B to reach 28% A and 72% B at 
48 min. Mobile phase A was KH2PO4 10 mM (H2O) at pH 7.00. B was a 
mixture methanol:acetonitrile 1:1 (v/v). UV detection was performed at 
210 nm. The chromatographic column was Phenomenex Synergi® MAX-
RP 4 µm 250×460 mm kept at 50 °C. Six impurities were separated and 
identified and it was possible to quantify five out of the six with 
reasonable accuracy and precision. (Miguel and C. Barbas 2003) 
A fast and sensitive high-performance liquid chromatographic 
method for determination of azithromycin in human serum using 
fluorescence detection was developed. The drug and an internal standard 
(clarithromycin) were extracted from serum using n-hexane and subjected 
to pre-column derivatization with 9-fluorenylmethyl chloroformate as 
labeling agent. Analysis was performed on a phenyl packing material 
column with sodium phosphate buffer containing 2 ml/l triethylamine 
(pH 5.9) and methanol (29:71, v/v) as the mobile phase. The standard 
curve was linear over the range of 10–500 ng/ml of azithromycin in 
human serum. The means between-days precision were from 13.3% (for 
10 ng/ml) to 2% (500 ng/ml) and the within-day precision from 11.9 to 
1.7% determined on spiked samples. The accuracy of the method was 
100.7–107.2% (between days) and 100.3–107.8% (within days). The 
limit of quantification was 10 ng/ml. The method was applied in a 
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bioequivalence study of four different azithromycin preparations in 12 
healthy volunteers. (Gholamreza Bahrami et al., 2005) 
A high-performance liquid chromatographic method with pre-
column derivatization and fluorescence detection was optimised and 
validated for the quantification of azithromycin (AZM) in plasma, blood 
and neutrophils. Clarithromycin (CLM) was used as an internal standard. 
Pre-column derivatization was done with 9-fluorenylmethyloxycarbonyl-
chloride. Recovery from blood and polymorphonuclear neutrophils 
(PMNNs) isolated by a gravity separation procedure was also assessed. 
Analytical separation was carried out using a C18 column as stationary 
phase and acetonitril–phosphatebuffer as mobile phase. Peak 
quantification was carried out by excitation at 267 nm and detection at 
317 nm. A lower limit of quantification of 0.042 ± 0.017 mg/l in plasma, 
0.119 ± 0.065 mg/l in blood and 0.072 ± 0.036 in water was achieved. 
Linearity was assessed from 0 to 1.5 mg/l in plasma and blood and from 
0–9 mg/l in water. The analytical method proved to be applicable in a 
pharmacokinetic study of AZM in a Cystic Fibrosis patient. (Erik Wilms 
et al., 2005) 
Azithromycin in pharmaceutical dosage forms can be assayed by 
voltammetric assay in which the oxidative behavior of azithromycin was 
studied at s glassy carbon electrode in different buffer systems using 
cyclic, linear sweep and differential pulse voltammetry. The oxidation 
process was shown to be irreversible over the entire pH range studied (5-
11) and was diffusion-absorption controlled. Analytical method with 
adequate precision and accuracy was developed for the determination of 
azithromycin in phosphate buffer at pH 7 as supporting electrolyte 
containing 10% methanol and 0.05M ammonium acetate. The peak 
current varied linearly with azithromycin concentration in the range 1-
15µg/ml. the procedure was successfully applied for assay of the drug in 
the pharmaceutical dosage forms. The method compares reasonably well 
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with reported HPLC method and can be a good alternative for the 
analytical determination of azithromycin because it is simple, fast and 
low cost; it has sufficient precision, accuracy and sensitivity. (Biljana et 
al., 2003)    
 A validated stability indicating thin-layer chromatographic (TLC) 
method of the analysis of azithromycin in bulk and capsule form was 
developed for both potential impurity and degradation products in raw 
material or finished product. The method based on precoated silica- gel 
TLC plate 60 f 254, and n-hexane- ethylacetate - diethylamine (75:25:10, 
v/v/v). The separated bands were detected as brown to brownish red spots 
after spraying with modified Dragendorff’s solution. The stability of 
azithromycin was studied under accelerated conditions in order to provide 
a rapid indication of differences that might result from a change in the 
manufacturing process or source of the sample. The forced degradation 
conditions include the effect of heat, moisture, light; acid-base hydrolysis, 
sonication and oxidation, the compatibility of azithromycin with 
excipients used were also studied in presence and absence of moisture. 
The amounts of azithromycin and azaerythromycin were calculated from 
the corresponding linear calibration curve. The method shows enough 
selectivity, sensitivity, accuracy, precision, linearity-range, and 
robustness to satisfy official requirements. The method developed can 
also be used for the purity testing of azithromycin raw material and 
capsules, content uniformity testing, dissolution testing, and stability 
testing of azithromycin capsules. (Alaa Kheder et al., 2003)  
 Azithromycin in medicine and bio-fluids was determined by 
ultrasensitive assay based on its enhanced luminol-H2O2 
chemiluminescence reaction with a flow injection technique. The 
enhanced chemiluminescence intensity was linear with the concentration 
of azithromycin used. A complete analytical process could be performed 
within 0.5 min. Including sampling and washing, with a relative standard 
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deviation of less than 0.5 min. The proposed method was applied 
successfully in the assay of azithromycin in pharmaceutical preparations 
human urine and serum without any pre-treatment procedure. (Zhenghua 
Song et al., 2003)  
A simple liquid chromatographic method was developed for the 
estimation of Azithromycin raw material and in pharmaceutical forms. 
The sample was chromatographed on a reverse phase C18 column and 
eluants monitored at a wavelength of 15 nm. The mobile phase used was 
a mixture of buffer(2.88 g ammonium phosphate monoacid, 45.6 ml of 
10% solution of tetra-butyl ammonium phosphate in 1000 ml water), 
acetonitrile and methanol (60:20:20) adjusted to pH 8. The mobile phase 
was degassed with helium, and the flow rate was 1ml/min at room 
temperature. The wavelength was set at 215 nm and the retention time 
was found to be 5 min. The method was found accurate, precise and 
sufficiently selective and it was applicable for azithromycin 
quantification, stability and dissolution test. (Patricia et al., 2002)  
An isocratic liquid chromatographic method with uv detection at 
215 nm was used for analysis of azithromycin in bulk samples. 
Azithromycin was separated from its synthesis intermediates and a 
degradation products as well as  six unknown impurities on an XTerre 
RP18 column at 70 Cº using mobile phase consisting of acetonitrile pH 
6.5 0.2 M K2HPO4- water(35:10:55 v/v/v). The flow rate was 1 ml/min. 
The XTerra stationary phase contains methyl groups that are incorporated 
in the bulk structure of the material, which allows for special selectivities. 
The validation of the method shows good selectivity, repeatability, 
linearity, and sensitivity. (Kamau et al., 2002)  
A simple and selective square-wave voltammetric (SWV) method 
has been developed for the determination of azithromycin in pure form, in 
pharmaceutical preparation and in biological samples. Determination of 
azithromycin was accomplished with hand-make carbon paste electrode 
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(CPE) in oxidative screen mode. The counter and reference electrodes 
were a Pt wire and a Ag/AgCl, respectively. Various parameters that can 
influence the peak signal (effect of buffer, ionic strength, accumulation 
time, pH and the composition of the paste) have been scrutinized. The 
best results were obtained in acetonitrile—aqueous 1 M sodium acetate–
acetic acid buffer (pH 4.6) containing 0.1 M KCl (1:9; v/v) using a 15% 
paraffin oil CPE. The limits of detection and quantification of the pure 
drug are 0.463 and 1.544 ppb (with the correlation coefficient, 
r=0.9785and the standard deviation, S.D.=0.1 (n=5), for the accumulation 
time of 60 s), respectively. The method was successfully applied to the 
determination of the drug in urine and two forms of pharmaceutical 
formulations. Recoveries were 99.2—100.5% with S.D.=0.1—and 0.8% 
(n=5). (Othman Abd El-Moaty Farghaly  and Niveen Abdel Latif 
Mohamed 2004) 
A simple, accurate and rapid spectrophotometric method for the 
estimation of azithromycin has been developed by the acidic hydrolysis 
of the drug with sulfuric acid and monitoring the absorbance at 482 nm. 
All variables affecting the reaction conditions such as sulfuric acid 
concentration, heating time, temperature and dilution solvents were 
carefully studied. Analytical parameters such as stability, selectivity, 
accuracy and precision have been established for the method and 
evaluated statistically to assess the application of the method. The method 
was applied successfully for the assay of azithromycin dihydrate in pure 
and pharmaceutical dosage forms as tablets, capsules and suspensions. 
The method was found to have the advantages for simplicity, stability, 
sensitivity, reproducibility and accuracy for using as an alternate to the 
existing non-spectrophotometric methods for the routine analysis of the 
drug in pharmaceutical formulations and also in pharmaceutical 
investigations involving azithromycin dehydrate. (Sultana N  et al., 2006) 
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A new, sensitive and fast pre-column on-line derivatization 
technique coupled with high-performance liquid chromatography using 9-
fluorenylmethyl chloroformate (FMOC-Cl) as labeling agent is described 
and validated for determination of azithromycin in human serum. After 
extraction of the drug from serum, the residue was reconstituted in 
mixture of acetonitrile-phosphate buffer (3:1, v/v; pH 8.5) and directly 
injected onto the chromatographic system. Continuous on-line 
derivatization and analysis of the compounds were successfully 
performed using in-tube elution of FMOC-Cl. The total time needed for 
derivatization and chromatographic analysis of the drug was 13 min. The 
assay was reliable and reproducible, with limit of quantification of 10  
ng/ml. The described technique may offer significant advantages over 
existing off-line derivatization methods using FMOC-Cl. (Gholamreza 
Bahrami and Bahareh Mohammadi  2006) 
The pharmacokinetics of azithromycin in plasma, lung tissue, and 
bronchial washing after oral administration of 500 mg (standard dose) 
versus 1000  mg daily for 3 days were compared. Samples were taken 
during surgery for lung resection at various time points up to 204  h after 
the last drug dose, and azithromycin levels were analyzed by HPLC 
method. Azithromycin was widely distributed within the lower 
respiratory tract; sustained concentrations of the drug were detectable at 
the last sampling time (204  h) in lung tissue and bronchial washing, with 
long term half-lives of 132.86 and 74.32  h at 500  mg daily and 133.32 
and 70.5  h at 1000  mg daily, respectively. Doubling the drug dose 
resulted in a remarkable increase in lung area under the curve (AUC, 
1318  hx µg g−1 vs 2502  hx µg g−1) and peak tissue concentration 
(9.13±0.53  µg g−1 vs 17.85±2.4  µg g−1). In addition to this, enhanced 
azithromycin penetration from plasma into bronchial secretion and lung 
tissue was evidenced by the increase in the ratio of AUCbronchial washing 
versus AUCplasma (2.96 vs 5.27 at 500 and 1000 mg, respectively) and 
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AUClung versus AUCplasma (64.35 vs 97.73 at 500 and 1000  mg, 
respectively). In conclusion, the exposure of lung and bronchial washing 
to azithromycin is increased by doubling the dose, which results in 
favorable pharmacokinetic profile of the drug in the lower respiratory 
tract. (Antonello Dipaolo et al., 2002) 
Quantification and amperometric detection of the macrolide 
antibiotics clarithromycin and roxithromycin were found by cyclic 
voltammetric studies and HPLC-electrochemical detection responses 
obtained in different temperatures (25.5 - 60°C) and different but almost 
isoelutropic binary, tertiary and quaternary mixtures of aqueous buffer 
(pH 7), methanol, acetonitrile and isopropanol. These conditions were 
also proved to be applicable for the quantitative detection of 
clarithromycin in human plasma using roxithromycin as an internal 
standard and vice versa. It was demonstrated that increased attention has 
to be paid to eluent composition and column temperature to ensure 
sensitive and reproducible electrochemical responses as well as regularly 
shaped peaks for both macrolides tested. (Pappa-Louisi et al., 2001) 
The intrapulmonary pharmacokinetics of orally administered 
clarithromycin (500 mg every 12 h for five doses) or erythromycin (250 
mg every 6 h for nine doses) were studied in 32 healthy adult volunteers. 
Four of the subjects, two in the clarithromycin group and two in the 
erythromycin group, were smokers. Bronchoscopy, bronchoalveolar 
lavage, and venipuncture were performed at 4, 8, 12, 24, and 48 h after 
administration of the last dose of clarithromycin and at 4, 8, and 12 h 
after administration of the last dose of erythromycin. Clarithromycin was 
measured by high-performance liquid chromatography, and erythromycin 
was measured by a microbiological assay. No systemic sedation was 
used. There were no major adverse events. The concentrations of 
antibiotics in epithelial lining fluid (ELF) were calculated by the urea 
dilution method. The volumes (mean ± standard deviation) of ELF were 
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1.9 ± 2.0 ml and 1.5 ± 0.7 ml in the clarithromycin and erythromycin 
groups, respectively (P > 0.05). There was no effect of smoking on the 
amount of bronchoalveolar lavage fluid recovered, the volume of ELF, or 
the number of erythrocytes present in the lavage fluid (P > 0.05 for all 
comparisons). The total number of alveolar cells, however, was almost 
three fold greater in the smokers versus that in the nonsmokers (P < 0.05). 
Clarithromycin was concentrated in ELF (range, 72.1 ± 73.0 
micrograms/ml at 8 h to 11.9 ± 3.6 micrograms/ml at 24 h) and alveolar 
cells (range, 505.8 ± 293.1 micrograms/ml at 4 h to 17.0 ± 34.0 
micrograms/ml at 48 h). 14-(R)-Hydroxyclarithromycin was also present 
in these compartments, but at lower concentrations than the parent 
compound. The concentrations of erythromycin in ELF and alveolar cells 
were low at 4, 8, and 12 h following the last dose of drug (range, 0 to 0.8 
± 1 microgram/ml in ELF and 0 to 0.8 ± 1.3 microgram/ml in alveolar 
cells). The clinical significance of any antibiotic concentrations in these 
compartments in unclear. The data suggest, and the study concludes, that 
clarithromycin may be a useful drug in the treatment of pulmonary 
infections, particularly those caused by intracellular organisms. (Conte et 
al., 1995) 
 Clarithromycin pharmacokinetics of bioequivalent generic 
clarithromycin tablets was investigated in healthy Thai male volunteers in 
a randomized, single dose (500 mg) fasting state, two period, crossover 
study design with a 1-week washout period. Plasma samples were 
collected over 24-hr. period after administration and were analyzed by 
using a validated method using high performance liquid chromatography 
(HPLC) with electrochemical detection. The time to reach the maximum 
concentration (tmax h)  the peak concentration (Lmaxng/ml) and the area 
under the curve (AUC0-00, ng/ml) of the reference and test formulations 
were 2.1 ± 0.7 vs 2.1 ± 0.7, 2474 ± 702 vs 2559±744 and 15803 ± 6120 
vs 17683 ± 6650 respectively. Relative bioavailability was 1.12. The 90% 
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confidence interval (90% CL) of Cmax and AUC0-00 were 95.6-110.8% 
and 103.5-122.5% respectively. Both formulations were equivalent in 
terms of rate and extent of absorption. Consequently, bioequivalence 
between the two formulations can be concluded. (Ornart et al., 2003)  
The bronchopulmonary and plasma pharmacokinetics of 
clarithromycin (CLA; 500 mg given twice daily for nine doses) or 
azithromycin (AZ; 500 mg for the first dose and then 250 mg once daily 
for four doses) were assessed in 41 healthy nonsmokers. Bronchoalveolar 
lavage was performed at 4, 8, 12, or 24 h after administration of the last 
dose. The concentrations (mean ± standard deviation) of CLA, 14-
hydroxyclarithromycin, and AZ were measured in plasma, epithelial 
lining fluid (ELF), and alveolar macrophage (AM) cells by high-
performance liquid chromatography assay. The concentrations of CLA 
achieved in ELF were 34.02 ± 5.16 micrograms/ml at 4 h, 20.63 ± 4.49 
micrograms/ml at 8 h, 23.01 ± 11.9 micrograms/ml at 12 h, and 4.17 ± 
0.29 microgram/ml at 24 h, whereas at the same time points AZ 
concentrations remained below the limit of assay sensitivity (0.01 
microgram/ml) for all but two subjects. The concentrations of CLA in the 
AM cells were significantly higher than those of AZ at 8 h (703 ± 235 
and 388 ± 53 micrograms/ml, respectively). However, the ratio of the 
concentration in AM cells/concentration in plasma was significantly 
higher for AZ than for CLA for all time points because of the lower 
concentration of AZ in plasma. The results indicate that while AZ has 
higher tissue concentration to plasma ratios, as shown by other 
investigators, the absolute concentrations of CLA in AM cells and ELF 
are higher for up to 8 and 12 h, respectively, after administration of the 
last dose.( Patel et al., 1996) 
A rapid, selective and sensitive high-performance liquid 
chromatographic method with spectrophotometric detection was 
developed for the determination of clarithromycin in human plasma. 
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Liquid–liquid extraction of clarithromycin and norverapamil (as internal 
standard) from plasma samples was performed with n-hexane/1-butanol 
(98:2, v/v) in alkaline condition followed by back-extraction into diluted 
acetic acid. Chromatography was carried out using a CN column 
(250 mm × 4.6 mm, 5 µm) under isocratic elution with acetonitrile–
50 mM aqueous sodium dihydrogen phosphate (32:68, v/v), pH 4.5. 
Detection was made at 205 nm and analyses were run at a flow-rate of 
1.0 ml/min at 40  °C. The analysis time was less than 11 min. The method 
was specific and sensitive with a quantification limit of 31.25 ng/ml and a 
detection limit of 10  ng/ml in plasma. The mean absolute recovery of 
clarithromycin from plasma was 95.9%, while the intra- and inter-day 
coefficient of variation and percent error values of the assay method were 
all less than 9.5%. Linearity was assessed in the range of 31.25–2000 
 ng/ml in plasma with a correlation coefficient of greater than 0.999. The 
method was used to analyze several hundred human plasma samples for 
bioavailability studies. (Hossein Amini and Abolhassan Ahmadiani 2005) 
A rapid, selective and sensitive HPLC assay has been developed 
for the simultaneous analysis of clarithromycin, its 14-hydroxy-
clarithromycin metabolite, and its decladinose acid degradation product, 
in small volumes of rat gastric juice aspirate, plasma and gastric tissue. 
Samples were extracted with n-hexane/2-butanol (4:1) and the internal 
standard was roxithromycin. A Kromasil ODS 5 µm (75×4.6 mm I.D.) 
column was used with a mobile phase consisting of acetonitrile/aqueous 
phosphate buffer (pH 7, 0.086 M) (45:55 v/v). The column temperature 
was 30 °C and coulometric detection was used at 850 mV using a screen 
voltage of 600 mV. The analysis time was less than 8 min. The limits of 
quantification for clarithromycin, 14-OH clarithromycin and decladinose 
clarithromycin were 0.15 µg ml−1 or lower in plasma (0.05 ml); 0.16 µg 
ml−1 or lower in gastric juice (0.2 ml); and 0.51 µg g−1 or lower for gastric 
tissue (0.25 g). The method was linear up to at least 20.3, 15.4 and 12.5 
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µg ml−1 for clarithromycin, 14-OH-clarithromycin and decladinose, 
respectively, in gastric juice aspirate and plasma and up to 40.6, 30.9 and 
25.0 µg g−1 in gastric tissue. The assay was applied to the measurement of 
clarithromycin, 14-OH-clarithromycin and, for the first time, decladinose 
clarithromycin in pharmacokinetic studies of gastric transfer of 
clarithromycin in individual rats. (Wibawa et al., 2003) 
An isocratic method for the identification and quantification of 
erythromycin  and related substances in enteric coated tablet formulations 
using high-performance liquid chromatography with ultraviolet (UV) 
detection  at 205nm was described. A novel method for sample preparing 
using a molecular weight centrifuge filter to reduce the interference 
observed from polymeric tablet coating material was also presented. 
Erythromycin HPLC assay were best run at high PH; these for various 
polymer columns were evaluated. The resulting HPLC method that was 
developed has several advantages over current pharmacopoeial assay 
methods for enteric –coated erythromycin tablets. Comparative data from 
both methods for the same batch of erythromycin tablets were presented. 
It has been found that the method can also be applied to various other 
erythromycin formulations, including particle coated tablets; 
Erythromycin stearate tablets, and erythromycin ethylsuccinate 
suspensions and formulation broth. A C18 polymeric column was used 
with a mobile phase composition of 0.02m potassium phosphate dibasic 
buffer (Ph 9) acetonitrile (60 : 40) and flow rate of 1ml/min. the method 
was found more sensitive, specific and rugged than the pharmacopoeial 
method. (Wardrop et al., 2000) 
 The pharmacokinetic advantages of erythromycin estololate over 
ethylsuccinate as determined by high performance liquid chromatography 
were investigated in 12 healthy volunteers after single dose and after 
repeated oral dose (every 8 hr.). Concentrations in plasma and urine of 
estolate, ethylsuccinate and erythromycin base was determined by High 
 30
performance Liquid Chromatography with electrochemichal detector. The 
maximum concentration of drug in the serum, the half-life, and the 
(AUC) area under the curve for erythromycin estolate were significantly 
greater than those of erythromycin ethylsuccinate after both regimens. 
The study underscores the need for a specific High-pressure liquid 
chromatography assay and the importance of wide variability, rate limited 
processes, changes with multiple doses, and the appearance of a second 
peak when one studies the pharmacokinetics of erythromycin esters. The 
pharmacokinetics data presented by HPLC in the study reinforce the 
clinical advantages of erythromycin estolate over erythromycin 
ethylsuccinate. (Daniel et al., 1988)  
A method using solid-phase extraction (SPE) combined with high-
performance liquid chromatography - ion trap tandem mass spectrometry 
(LC–MS–MS) has been developed for determination of trace 
concentrations of erythromycin-H2O (ETM-H2O), roxithromycin (RTM) 
and tylosin (TLS) in natural and waste water matrices. These macrolides 
(MLs) were extracted from water samples using Oasis HLB cartridges, 
and the average recovery was 93.6 ± 8.6, 92.1 ± 10.0, and 94.3 ± 8.9% for 
ETM-H2O, RTM and TLS in surface water, respectively. For water from 
the influent of a wastewater treatment plant (WWTP), the average 
recovery was 84.8 ± 14.0, 83.2 ± 13.1, and 86.1 ± 13.4% for ETM-H2O, 
RTM and TLS, respectively. Method detection limits in a natural water 
matrices were 0.07, 0.03, and 0.05  µg/l for ETM-H2O, RTM, and TLS, 
respectively. Fragment or product ions from MS spectra using in-source 
collision-induced dissociation and MS-MS spectra have been identified. 
The accuracy and day-to-day variation of the method fell within 
acceptable ranges. The method was evaluated by studying the occurrence 
of the three macrolides on a river and a WWTP in northern Colorado. 
None of the antibiotics were detected in the stream except immediately 
downstream of a WWTP, a result consistent with their presence in the 
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influent and effluent of the treatment facility. (Yang and K. H. Carlson-
2004) 
A reliable and sensitive procedure was presented for the analysis of 
erythromycin (ERY) and oleandomycin (OLE) in food of animal origin, 
such as meat, liver, kidney, raw milk and egg. The method was based on 
a solid-phase extraction clean-up with a cation exchange cartridge, a 9-
fluoromethylchloroformate (FMOC) precolumn derivatization and a 
separation by HPLC with fluorometric detection. The selectivity was 
satisfactory enough to control ERY and OLE residues as not many 
interfering peaks were observed for various food matrices. The 
macrolides recoveries of the total procedure were low, although >50%. 
However, addition of an internal standard (roxithromycin) corrected for 
recovery to give satisfactory quantitative results for repeatability, 
linearity, detection and quantification limits and mainly accuracy. (Edder 
P et al., 2002) 
A sensitive and selective liquid chromatography-electrospray 
ionization mass spectrometry (LC-ESI-MS) method was developed for 
simultaneous identification and quantification of erythromycin 
ethylsuccinate and erythromycin in human plasma, which can be well 
applied to clinical study. The method was based on liquid–liquid 
extraction, followed by a LC procedure with an ODS C18 column, and 
mixture of acetonitrile and 1.67  mmol/l acetic acid as mobile phase. MS 
detection was performed using a single quadrupole mass spectrometer in 
positive selected ion monitoring (SIM) mode. The method was validated 
to be linear, precise and accurate. The lower limit of quantification of 
erythromycin ethylsuccinate and erythromycin were both 0.5  ng/ml. The 
proposed method enables the unambiguous identification and 
quantification of erythromycin ethylsuccinate and erythromycin for 
clinical drug monitoring. (Yi Gu et al., 2006) 
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An analytical method for simultaneous determination of 
erythromycin propionate and its active metabolite, erythromycin base, in 
human plasma by high-performance liquid chromatography-electrospray 
mass spectrometry (HPLC–ESI-MS) was developed and validated. 
Roxithromycin was selected as the internal standard. The samples were 
directly injected after simple deproteinized procedure only. The 
separation was achieved on a Johnson Spherigel analytical column 
packed with 5  µm C18 silica, employing acetonitrile -0.1% formic acid 
aqueous solution (50:50) as mobile phase. The quantification of target 
compounds was obtained by using a selected ion monitoring (SIM) at m/z 
790.7 for erythromycin propionate, m/z 734.7 for erythromycin base and 
m/z 837.8 for roxithromycin. The correlation coefficients of the 
calibration curves were better than 0.997 (n = 6), in the ranges from         
2  ng/ml to 1  µg/ml, and from 1 to 10  µg/ml for erythromycin propionate 
and base. The method can provide the necessary sensitivity, precision and 
accuracy to allow the simultaneous determination of both compounds in a 
patient's plasma following a single administration of erythromycin 
propionate capsule (500 mg erythromycin base equivalent) (Weitao Xiao 
et al., 2005). 
A simple, isocratic liquid chromatographic (LC) method using volatile 
mobile phase constituents for the identification of erythromycin and 
related substances in erythromycin samples was described. For method 
development, evaporative light scattering detection (ELSD) was used. An 
XTerra™ RP18 column was used at 70  °C with a mobile phase consisting 
of acetonitrile–isopropanol–0.2 M ammonium acetate pH 7.0–water 
(165:105:50:680). Mass spectral data were acquired on an ion trap mass 
spectrometer equipped with an electrospray interface operated in the 
positive ion mode. First, a library was created using MS/MS and MSn 
spectra of reference substances available in the laboratory. Using these 
reference spectra as interpretative templates, eight novel related 
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substances in erythromycin samples were identified: N-
demethylerythromycin E, erythromycin E N-oxide, anhydroerythromycin 
C, N-demethylerythromycin B, anhydro-N-demethylerythromycin A, 
pseudoerythromycin E enol ether, EF lacking the neutral sugar and EA 
lacking the neutral sugar. (Satish Kumar Chitneni et al., 2004) 
Two chromatographic methods were developed for the 
determination of erythromycin A (EA) residues in animal tissues (muscle, 
liver, kidney and fat of cattle, pigs and poultry) and cow’s milk. In 
addition to a more traditional method using electrochemical detection, an 
original alternative method based on UV detection at 236 nm, by 
pretreating to create a chromophore in the molecule was developed. An 
internal standard was used with both methods to check the variability of 
the analytical system. Analysis times and performance were compared. 
The recovery of EA from various matrices was greater than 95%. For 
both methods the quantification limit for EA was 0.25 mg ml21 for 
plasma, 0.025 mg g21 for milk and 0.125 mg g21 for the other biological 
matrices. The methods can be used to check for EA residues in these 
matrices; in fact, the statutory maximum residue limits (MRLs) of EA 
were 0.4 mg g21 in muscle, kidney, liver and fat of beef cattle, sheep, 
pigs and poultry, and 0.04 mg g21 in cow’s and sheep’s milk. (Dreassi et 
al., 2000) 
Corneal pharmacokinetics of topically applied azithromycin and 
clarithromycin was determined in rabbits using both bioactivity assay & 
HPLC analysis. It has been found that corneal concentration of 
azithromycin increased with drug dosage and duration of application. 
Rabbits treated with azithromycin tolerated the drug well without signs of 
irritation. Clarithromycin was undetectable in corneal tissue by 
bioactivity assay and HPLC for all rabbits. Some rabbits treated with 
clarithromycin had signs of ocular surface irritation. The study concluded 
that measurable concentrations of azithromycin are achieved in corneal 
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tissue after topical application in a rabbit model, and the drug is well 
tolerated, hence it may be useful antibiotic for the topical treatment of 
human corneal infections, but clarithromycin in currently available 
formulations may not be effective because of poor tissue penetration. 
(Jonas et al., 2004)  
Two sensitive methods for the determination of the azalide 
antibiotic azithromycin in human serum were compared. High-
performance liquid chromatography (HPLC) and a microbiological assay 
were simultaneously applied to 768 serum samples obtained in a clinical 
study. There was excellent agreement between the azithromycin 
concentrations measured by HPLC and by the bioassay. The correlation 
coefficient for the two methods was r2 = 0.96. The precision and the 
sensitivity of the methods were found to be very similar. (Riedel KD et 
al., 1992) 
 
 
1.3-Basic Assay Techniques & Principles:- 
1.3.1-Biological Testing: 
 Biological testing includes the quantitative assay of drugs by 
biological methods as well as the application of qualitative biological 
tests. Such testing utilizes intact animals, animals’ preparations, isolated 
living tissues, or microorganism. 
 The majority of currently available therapeutic agents are 
substances of known chemical composition, which can be assayed by 
quantitative chemical or physical analysis. There remains, however, a 
limited number of useful drugs, which cannot be assayed satisfactory by 
chemical or physical means. Such drugs, which are primarily of natural 
origin, are assayed by biological methods. Biological standardization 
procedures are generally less precise, more time consuming, and more 
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expensive to conduct than chemical assays; therefore, they are generally 
reserved for use mainly:- 
1- If the chemical identification of the active principle has not been 
fully elucidated. 
2- If no adequate chemical assay has been devised for the active 
principle, although its chemical structure has been established. 
E.g., Insulin. 
3- If the drug is composed of a complete mixture of substances of 
varying structure and activity, e.g., digitalis, posterior pituitary 
hormone. 
4- If purification of the crude drug, sufficient for performance of a 
chemical assay, is not possible or practical, e.g., the separation of 
vitamin D from certain irradiated oils. 
5- If the chemical assay does not avail indication of biological 
activity, due for example, to lack of differentiation between active 
and inactive isomers. 
There are several situations in which factors such as specificity, 
sensitivity, or practicability dictate the use of biological rather than a 
chemical procedure. (Remington’s 1990)  
1.3.2-Principles of agar diffusion: 
 Agar diffusion (plate) method for microbiological assay depends 
on quantitative comparison of the effect of two substances on the growth 
of a suitable microorganism in a nutrient medium. The two substances are 
standard and a sample whose potency is to be determined. The effect may 
be to inhibit the growth, as in case of antibiotics or to promote the 
growth, as the case of vitamins and amino acids (Hewitt, 1977). 
1.3.3-The plate assay:- 
 Nutrient agar is melted and its temperature reduced to 48°c. A 
small volume of suspension of sensitive organism is added by pipette and 
gently but well mixed to give a uniform dispersion in the agar medium. A 
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suitable volume (15-20) ml of the seeded agar is pipetted in petri-dishes 
to give a layer of uniform thickness (about 3-5mm). After solidification, 
the agar plates are ready for use and may be refrigerated until required. 
(Hewitt, 1977) 
Two or more concentrations from both standard and test samples 
are applied to reservoir at appropriately spaced positions on the plate. 
These positions may be in accordance with randomized pattern for each 
plate in a set comparing on assay. The reservoir is made either by 
removing small cylinders of agar using cork borer or gem stainless steel 
punch. Specially designed stainless steel cylinders placed on the surface 
of the agar can also be used as reservoir. Small filter paper discs or fish 
spine beads can be used after dipping them in the test solution and surplus 
liquid is drained and then placed on the surface of the agar (Hewitt, 
1977). 
 For the first two procedures, a standard volume of test is added to 
each reservoir. The solution is allowed to diffuse into the agar at room 
temperature or lower for an hour or perhaps more, and then the plates are 
incubated, usually over night (Hewitt, 1977).  
 After incubation, clear zones surround the points of application of 
the antibiotic, whereas in other parts of the plate growth of 
microorganism causes turbidity. Zones boundaries are usually clearly 
defined, although the sharpness of definition varies according to test 
organism, the density of the incoculum and the antibiotic. (Hewitt, 1977)  
  Inhibition zone diameters are measured. The relationship between 
mean response (zone diameter) to each test solution and the concentration 
of that test solution is the quantitative basis of assay. (Hewitt, 1977)  
1.3.4-Factors affecting the assay method:- 
1.3.4.1-Reference standard 
 These are preparations of the antibiotics to which a potency 
expressed as unit/mg of the drug material has been assigned by 
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international or national agreement. They are supplied on request in small 
quantities to be used as reference standards when a laboratory standard is 
established. It is axiomatic that very great care should be taken when 
establishing a laboratory standard from the international standard. (Hugo 
& Russel, 1980)  
1.3.4.2-Cultures: 
 The assay needs a pure culture of the selected sensitive 
microorganism. Clear sharp-edged zones of inhibition for diffusion assay 
and suitable difference in response to graded doses for turbidimeteric 
assay are necessary. Test organism should give an even growth without 
tendency to clumping to ensure reproducible system. The culture should 
be in the logarithmic phase of growth. (Hugo & Russel, 1980)   
1.3.4.3-Medium: 
 Besides supporting the growth of the test microorganism, the 
medium should not work as an antagonist for the antibiotic used usually 
the design of the assay incorporates at least three dose levels of standard 
and test product for precised assay, and four to eight replicates at each 
dose level for diffusion, and two to four replicates for dilution assays are 
desirable. Extraction of different pharmaceutical forms of antibiotics 
must be perfect by choosing the proper buffer (phosphate, citrate or 
acetate) with the proper adjusted pH. (Hugo & Russel, 1980)  
1.3.4.4-Kinds of agar assay:- 
 Agar diffusion assay can be put in one of three categories. One is 
one-dimensional diffusion such as diffusion in test tubes or in capillary 
tubes. Another is two-dimensional diffusion such as the radial diffusion 
from cups in the agar. The third is three-dimensional diffusion from 
cylinders, beads or discs placed on the surface of agar. (Kavanah, 1972). 
1.3.4.5-Surface inoculation: 
 This is a complicated method because the inoculun size can not be 
expressed per milliliter of agar, and the critical population for dense 
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surface colonies or confluent growth is unknown. Zones are larger than in 
deep seeded agar plates, but the critical concentration is greater. 
(Kavanah, 1972). 
1.3.4.6-Heated culture:- 
 The killing of part of the inoculum by heat may decrease the scatter 
of variables, such as sensitivity and germination times of individual cells 
in the populations. Sharp zones are achieved in this way but only at the 
expense of the introduction of more factors to control. (Kavanah, 1972). 
1.3.4.7-Spores:- 
 The use of spore’s suspensions in place of vegetative organisms 
seems to give very reproducible results. A function of germination is thus 
added to the initial lag period. It must be remembered that factors 
affecting germination (nutrients, temperature, pretreatment) will differ 
from those affecting vegetative growth. These factors must be controlled 
and made as identical as possible for both standard and tests. (Gould 
G.W. & Hurst, 1969)  
1.3.4.8-Incubation temperature:- 
 One of the important causes of inaccurate diffusion assays is non 
uniform incubation temperature. Temperature of incubation influences 
both zone and the slope of the dose response line. A temperature 
difference of 0.1 °C between incubation temperature of standard and 
sample could make a measurable difference. Differences of (4-5 °C) 
between adjacent areas in air incubators are not uncommon. Not only 
terminal temperature, but also the rate of heating of the content of the 
plate influence zone size and slope. Many manufactures developed 
advanced incubators that make homogeneous temperature in all parts of 
the incubators. (Kavanah, 1972). 
1.3.4.9-Dosing:- 
 Dosing is an operation with unavoidable inherent errors. Current 
practice is to measure the dose accurately with an automatic pipette. The 
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doses are put into a hole in the agar, in a cylinder or in a disc. The 
inherent error is caused by the time that elapses between the first 
application and the last one. The time becomes prediffusion time the 
moment the first dose is applied. In effect each dose has a different slope 
of its prescribed amount- response line. Only when agar diffusion is 
mechanized that all samples and standards are treated in an identical 
manner with respect to time and temperature will be potenial potency of 
this assay is achieved. (Kavanah, 1972). 
1.3.4.10-The sharpness of the zone edge:- 
 The edge of the zone dividing inhibition and growth may vary from 
very sharp to complete gradation over a considerable distance. Difficulty 
in the estimation of the edge (50% inhibition) will therefore decrease the 
accuracy of assay. No complete theory of the sharpness and visibility of 
the zone edge is available. Factors known to affect this are:- 
a- The ratio of the reservoir concentration to critical concentration 
(which affects concentration gradient). 
b- The use of limited amount of antibiotics in reservoir producing a 
maximum concentration at the position of the zone edge before it is 
formed which may produce double zoning. 
c- An increased time of diffusion decreasing the concentration 
gradient when the zone edge is formed. 
d- The critical time (T0) and therefore all factors affecting the number 
of generations (n1) and doubling time (G). The most important are 
temperature and the size of inocula (ratio of N0/N1). N1 is the 
critical population and N0  is the viable count of the population. 
e- The amount of growth and its opacity after the formation of the 
zone prior to the zone being measured. This will depend on the 
media composition (nutrients) and atmosphere (O2 / H2O). 
Diffusion of unused nutrients from the zone of inhibition may 
cause enhancement of growth at the edge. Microaerophilic 
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conditions may abolish sharpness of the edge or give zones of a 
different size. The morphology of colonial growth, the opacity of 
confluent growth or colonies, capsules formation, sporulation, 
motility, and surface configuration may all affect visibility. 
Secondary effects of the antibiotic such as lysis may further 
increase zone size. The mode and intensity of illumination will 
affect visibility. The amount of transmitted, scattered, and reflected 
light from the agar surface and the bacterial growth will determine 
the contrast between the zone and the growth culture. 
f- Scatter of antibiotic sensitivities of individual organisms in the 
population to the antibiotic. The distribution of generation times in 
the presence of sublethal concentrations of antibiotics differs from 
the normal. (Kavanah, 1972). 
1.3.4.11-The slope of the assay line:- 
 With a constant antibiotic concentration in the reservoir the slope 
of the straight line obtained by plotting in mo (The conc of antibiotic in 
contact with the agar culture) against x2 (The square of the distance 
diffused and not the zone diameter) is determined by D (Diffusion 
coefficient) and T (Time of diffusion). For a valid assay to give parallel 
lines DT must be constant and equal for standard and test. The accurate 
timing of the beginning of incubation and the addition of antibiotic is first 
necessity. Moreover the similar treatment of standards and test samples 
necessitates the design of operations on a statistical basis. All designs 
however, will be rendering useless unless the temperature controls are 
adequate. Plates in incubators heat up slowly and take different times 
according to their position. Antibiotic solutions should be prewarmed to 
the temperature for diffusion before being added to reservoir. Oxygen 
availability is a highly important factor and some organisms and 
antibiotics fail to produce sharp zones under microaerophilic conditions. 
The sensitivity of strains varies, and care should be taken that subcultures 
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of standard strains for assay are reasonably constant. When destructive 
enzymes, such as penicillinase are produced by the test organism the size 
of the inoculum greatly influenced the size of the zones. The normal 
formulas can’t be applied. Assay strains of organisms should be carefully 
chosen and tested to show that they do not produce destructive enzymes 
or antagonists. Standardization of these conditions is particularly 
important so as not to affect the slope of the assay. (Kavanah, 1972).  
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1.4- Purpose of the study 
Microbiological assay of antibiotics is very important method of 
analysis because in addition to quantifying antibiotics, it also 
demonstrates whether the antibiotic retains its activity or not. However 
it’s affected by many factors and need many precautions in order to get 
reliable results. While HPLC methods are also very important in analysis 
of both antibiotics and their metabolites (in case of decomposition of the 
drugs), their main drawbacks are that they do not give any information 
about the activity of the antibiotics. 
The aim of this study is:- 
1- To evaluate a microbiological assay method for azithromycin and 
clarithromycin. 
2- To see weather erythromycin can be assayed by HPLC method. 
3- To compare the results of microbiological assay with HPLC assay 
methods or spectrophotometric method. 
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2. Materials and Methods 
2.1- Materials: 
2.1.1- Antibiotics:- 
1- Erythromycin stearate 250 mg film coated tablets (Amipharma 
Laboratories (Sudan). 
2- Erythromycin stearate film coated tablets (Epomycin) (EIlE 
pharmaceuticals-Sudan)  
3- Erythromycin stearate film coated tablets (General Medicine 
Company- Sudan). 
4- Azithromycin Dihydrate 250 mg capsules (Zocin)-(Advanced 
Pharmaceutics Industry – Jordan) 
5- Azithromycin  Dihydrate 250 mg capsules (Zomax)-(Elhikma 
pharmaceuticals-Jordan) 
6- Azithromycin  Dihydrate 250 mg capsules (Azithrolyd)-(Elfaris 
pharmaceutical-Syria) 
7- Clarithromycin film coated tablets 250 mg (Claritop)-(RAM 
Pharmaceutical Industry – Jordan). 
8- Clarithromycin film coated tablets 250 mg (Clarem)-(Remedica 
Ltd. Cyprus) 
9- Clarithromycin film coated tablets 250 mg (Clarix)-(Pharma 
International Co. Jordan). 
10- Erythromycin powder (Working standard) (Sudan National 
Quality Control Lab – Supplied By WHO). 
11- Azithromycin powder (Working standard) (Sudan National 
Quality Control Lab – Supplied By WHO). 
12- Clarithromycin powder (Working standard) (Sudan National 
Quality Control Lab – Supplied By WHO). 
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2.1.2- Chemicals: 
1- Methanol.; Scharlau, Spain 
2- KH2PO4.   BDH, England 
3- HCL. Scharlau, Spain 
4- NaOH. Scharlau, Spain 
5- Phosphoric acid. Scharlau, Spain 
6- K2HPO4. BDH, England 
7- Acetonitrile. Scharlau, Spain 
8- 2-methylpropan-2-ol. Scharlau, Spain 
9- Disodium hydrogen orthophosphate. BDH, England 
10- Citric acid. Scharlau, Spain 
11- KOH. Scharlau, Spain 
2.1.3- Microorganism:- 
 Bacillus pumilus ATCC No. 8241 (American Type Culture 
Collection). 
2.1.4- Culture media: 
1- Antibiotic medium No. 1 (USP. 28 & BP. 2004) .(Himedia, 
PVT, Ltd. India) 
Formula:- 
Peptoune   6 g/L.  
Trypton   4 g/L 
Yeast extract  3 g/L 
Lab – Lemco powdeer 1.5 g/L 
Dextrose                      1.5 g/L 
Agar No. 1   11.5 g/L 
PH 6.5 (approximately). 
2- Antibiotic median No. 32 
Same as antibiotic medium 1 in addition to 0.3 g of manganese 
sulfate. 
 
 45
2.1.5- Buffer: 
 Buffer No. 3 pH 8 (USP-28) dibasic potassium phosphate 16.73 g. 
Mono basic potassium phosphate 0.573 g. water to 1000 ml. 
Adjust the pH with 10N KOH or 18N HCl. 
2.1.6- Instruments: 
1- Autoclave: Astell-lab.service co., London, S.E.b, England. 
2- Balance: KERN& sohn GembH-germany. 
3- Cork borer: England. 
4- Oven: Germany( memmert). 
5- Water bath: Cambridge-England(Grant Instrument Co. Ltd 
Barrington). 
6- Incubaters : (SANYO). 
7- PH meter England 
8- Refrigerator: (SANYO). 
9- Shaker England 
10- Colony-counter: (Gallenkamp, England). 
11- Standard dropping pipette : (Assipette, Germany). 
12- Needle : Germany. 
13- Petri dishes : Germany. 
14- Bunsen Flame : Germany. 
15- Test tubes : Germany. 
16- Sonicater : Bandelin electronic, Berlin, Germany. 
17- Lamda-2 UV/VIS Spectrophotometer : Perkin, Elmer. 
18- HPLC : Sykam, Germany. 
2.2- Methods: 
2.2.1- Microbiological assay:- 
2.2.1.1-Condition for assay: 
- Microorganism used for the three macrolide antibiotics is 
Bacillus pumilus ATCC 8241. 
- All plates incubated at 37 °C for 18 hr.  
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- Solvent used for assay is methanol. 
- Diluent used was Buffer 3 pH 8. 
- Medium used was antibiotic medium No. 1. 
- Median dose for antibiotics as follows:  
Erythromycin 10 µg/ml. 
Azithromycin 1 µg/ml. 
Clarithromycin 1 µg/ml. 
2.2.1.2- Preparation of the medium for test organism: 
 Medium to maintain test organism was antibiotic med. No. 32. 32 
gram of medium 32 were dissolved in sufficient amount of distilled water 
to produce 1000ml. the pH was adjusted and sterilized in the autoclave. 
2.2.1.3- Preparation of the medium for antibiotic assay:  
28 gram of medium No. 1 were dissolved in sufficient amount of distilled 
water to produce 1000 ml. The pH was adjusted and sterilized in 
autoclave. 
2.2.1.4- Preparation of Buffer:- 
 Buffer No. 3 0.1M pH 8 (USP-28). 16.73 g of dibasic potassium 
phosphate and 0.573 g of Monobasic potassium phosphate were dissolved 
in sufficient amount of water to produce 1000 ml. 
Adjust the pH with 10N KOH or 18N HCl. 
2.2.1.5- preparation of inoculum: 
 Spore suspensions of Bacillus pumilus to be used as inocula were 
prepared by growing the organism at 35 °C for 7 days on surface of agar 
medium- 32 slope which is contained of manganese sulphate. The growth 
which consists mainly of spores was washed off by sterile water and 
heated at 70 °C for 30 min. and then diluted to concentration of 10X106 
CFU per ml. The spore suspension was stored at 4 °C. (B.P 2004). On the 
day of analysis the medium was melted and then inoculated with 1% v/v 
of the suspension of the organism. 
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2.2.1.6- Preparation of serial dilutions for standard and sample:-  
 In order to assess the validity of the assay, three doses of the 
reference substance (standard) and three doses of the antibiotic being 
examined having the same presumed activity as the doses of reference 
substances were prepared (B.P 2004). The solutions of antibiotic being 
examined and the solutions of the reference substance were arranged in 
an alternate manner to avoid interaction of the more concentrated 
solutions (B.P 2004). 
2.2.1.6.1- Preparation of serial dilutions for standard Erythromycin: 
 A weight of standard erythromycin stearate (604 µg/mg potency 
2.4% water content) equivalent to 50 mg erythromycin was dissolved in 
few mls of methanol in volumetric flask and completed the volume to 50 
ml. From this solution 2 ml was taken and transferred to 100 ml 
volumetric flask and completed the volume with phosphate buffer to give 
the first dilution S3 = 20 µg/ml. from S3 solution double fold serial 
dilutions were carried out in 50 ml volumetric flask to give 
concentrations of 10 µg/ml = S2 and 5 µg/ml = S1 of Erythromycin. 
2.2.1.6.2- Preparation of serial dilutions for Erythromycin samples:- 
 10 tablets from the sample were weighted and powdered. A weight 
assumed to be equivalent to 50 mg of Erythromycin (according to label) 
was dissolved in few mls of methanol in volumetric flask and completed 
the volume to 50 ml in volumetric flask, and filtered. From this stock 
solution 2 ml was transferred to 100 ml volumetric flask and completed 
the volume with phosphate buffer (B3) to give solution assumed to 
contain 20 µg/ml = u3. From the last solution double fold dilutions were 
carried in two 50 ml volumetric flask to gain 2-serial concentrations 
assumed to contain 10 µg/ml = u2 and 5 µg/ml = u1 of the sample. 
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2.2.1.6.3-Preparation of serial dilutions for standard 
azithromycin and clarithromycin :- 
A weight of the standard Azithromycin dihydarate and 
clarithromycin equivalent to 20 mg Azithromycin and clarithromycin 
were dissolved in few mls of methanol in volumetric flask and completed 
the volume to 100ml methanol in volumetric flasks. From these solutions 
2ml were taken and transferred to another 100 ml volumetric flasks and 
completed the volume with phosphate buffer 3 to give a dilution of 4 
µg/ml (S3) of azithromycin and clarithromycn. From S3 solution double 
fold dilutions was carried in two 50ml volumetric flasks to give two serial 
concentrations of 2 µg/ml (s2) and 1 µg/ml (s1) of standard drugs. 
2.2.1.6.4-Preparation of serial dilutions for azithromycin and 
clarithromycin samples:- 
A- Azithromycin  
Content of 10 capsules of azithromycin Dihydrate were completed 
removed and weighed. A weight assumed to be equivalent to 20 mg of 
azithromycin was dissolved in few mls of methanol in volumetric flask 
and completed the volume to 100 ml methanol in volumetric flask. From 
this solution 2 ml were taken and transferred to 100 ml volumetric flask 
and completed the volume with phosphate buffer 3 to give a 
concentration of 4 µg/ml (u3) of azithromycin, and From u3 solution 
double fold dilutions were carried in two 50ml volumetric flasks to give 
two serial concentrations of 2 µg/ml (u2) and 1 µg/ml (u1) of 
azithromycin sample. 
B- Clarithromycin 
10 tablets of clarithromycin were weighed and powdered. A weight 
assumed to be equivalent to 20 mg of clarithromycin was dissolved in 
few mls of methanol in volumetric flask and completed the volume to 100 
ml methanol in volumetric flask. From this solution 2 ml were taken and 
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transferred to 100 ml volumetric flask and completed the volume with 
phosphate buffer 3 to give a concentration of 4 µ/ml (u3) of 
clarithromycin, and From u3 solution double fold dilutions were carried in 
two 50ml volumetric flasks to give two serial concentrations of 2 µ/ml 
(u2) and 1ug/ml (u1) of clarithromycin sample. 
2.2.1.7- Procedure: 
Agar Diffusion Method:  
Sterile petri dishes were filled to a depth of 3-4 mm with prepared 
Inoculated agar medium and allowed to solidify at room temperature for 
30 min. Identical wells were aseptically digged in the agar by sterile cork 
borer. Serial dilutions of standard and test antibiotics were applied in the 
holes with specific configuration (alternating) by standard dropping 
pipette. The plates were kept at room temperature for two hours then in 
an incubator at suitable temperature for sixteen hours. Inhibition zone 
diameters were measured and the potency of the samples were calculated 
from the recorded data. (USP-28, BP 2004). 
2.2.2- HPLC method 
2.2.2.1- Clarithomycin 
2.2.2.1.1- Preparation of mobile phase:- 
A mixture of methanol and 0.067 M monobasic potassium 
phosphate (650:350) was prepared and the pH adjusted with phosphoric 
acid to 4 and then the mixture was filtered and the filtrate used as mobile 
phase. (USP-28) 
2.2.2.1.2- Preparation of standard solution:- 
* Stock solution  
 Standard powder of clarithromycin equivalent to 400 mg was 
accurately weighed and dissolved in 100 ml methanol to produce a 
concentration of 4 mg/ml. 
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* Standard working solutions for calibration curve:- 
 Five solutions from 2 mg to 1.25 mg/ml were prepared by double 
serial dilutions by taking a volume from stock and added the same 
volume from mobile phase and then follow the procedure of double 
dilutions till the last solution was prepared. 
2.2.2.1.3-  Sample preparation:- 
 10 tablets of clarithromycin were weighed and finely powdered, 
and the accurately weighed powder sample was suspended in methanol in 
order to obtain 1 mg/ml of clarithromycin, the suspension was shaken by 
mechanical means for 30 min and then left on the bench to allow any 
insoluble matter to settle. A volume from supernatant solution was 
transferred and diluted by the same volume from mobile phase and 
filtered. The filtrate was used as assay preparation. (USP-28). 
2.2.2.1.4-  Chromatographic system:-  
 The HPLC system consisted of HPLC-pump (Sykan) equipped 
with auto sampler injector (Sykan), which was provided with 20ml 
sample loop, 210 nm wave length and UV detector (sykan). The column 
used was Alttech Hypersil LI (ODS C18) 4.6 mm x 15 cm and it’s 
maintained at constant temperature of about 50 °C. The flow rate was 
about 1ml per min. 
2.2.2.1.5-  Procedure:-  
 Five concentrations of the standard were injected starting from the 
lowest dilution; each dilution was injected three times to study the system 
linearity response. Three injections from the sample were applied and 
compared with the middle dilution of the standard in which the 
concentration of the sample assumed to be equal to the middle 
concentration of the standard. All injections were carried out on the same 
day and by the same operator. 
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2.2.2.2- Erythromycin:- 
2.2.2.2.1-  Preparation of the mobile phase:- 
 A mixture of 400 ml water, 50 ml of 3.5% w/v solution of 
dipotassium hydrogen orthophosphate and 165 ml of 2-methylpropan-2-
ol and 30 ml of acetonitrile was prepared and diluted with H2O to 1000 
ml. The solution prepared was adjusted to pH. 9 with 1M 
orthophosphoric acid and KOH. 
2.2.2.2.2- Preparation of the standard solution:- 
* Stock solution:- 
 Standard powder of Erythromycin equivalent to 200 mg was 
accurately weighed and dissolved in 100ml of a mixture of 1 volume 
methanol and 3 volumes of citro-phosphate buffer pH 7.0 to produce a 
concentration of 2 mg/ml. The solution was filtered. 
* Standard solutions for calibration curve:- 
 Five solutions from 1 mg/ml to 0.0625 mg/ml of erythromycin 
standard were prepared by diluting the stock solution with a mixture of 1 
volume methanol and 3 volumes of citro-phosphate buffer pH 7.0. 
2.2.2.2.3-  Sample preparation:- 
 10 tablets of erythromycin were weighed and finely powdered and 
accurately weighed powder sample was suspended in a mixture of 1 
volume of methanol and 3 volumes of citro-phosphate buffer pH 7.0 to 
produce a concentration assumed to be 0.25 mg/ml of erythromycin. The 
suspension was sonicated for 15 min and filtered and the filtrate was used 
as assay preparation. 
2.2.2.2.4- Chromatographic system:- 
 The HPLC system consists of HPLC pump(Sykan) equipped with 
auto sampler injector (Sykan) which was provided with 20 µl sample 
loop, UV detector(Sykan) and the wave length adjusted to 215 nm, colum 
used was (25 cm X 4.6 mm) packed with styrene-divinylbenzene 
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copolymer (8 µm) with a pore size of 100 nm. It’s maintained at constant 
temperature of 70°c. The flow rate was about 1.5 ml/min. 
2.2.2.2.5-  Procedure:-    
Similar to that for clarithromycin (2.2.2.1.5) 
2.2.3- Spectrophotometric assay 
Azithromycin: 
2.2.3.1- Preparation of serial dilution for standard azithromycin 
dihydrate:  
A weight of standard azithromycin dihydrate equivalent to 400 mg 
azithromycin was dissolved in few mls of methanol in a volumetric flask 
and the volume completed to 50 ml with methanol. The solution was 
sonicated for 15 min. and filtered. Fives double-folds dilutions in 50 ml 
volumetric flasks were carried using methanol to give concentrations of 
0.25, 0.5, 1.0, 2.0, 4.0 mg/ml of the standard azithromycin. 
2.2.3.2- Sample preparation:  
Content of 10 capsules of azithromycin dihydrate were completely 
removed and weighed. A weight equivalent to 100 mg of azithromycin 
was dissolved in few mls of methanol in 50ml volumetric flask and the 
volume completed to 50 ml with methanol. The solution was sonicated 
for 15 min. and filtered. 25 ml from the filtrate was pippeted to another 
50ml volumetric flask and the volume was completed with methanol. The 
final concentration of this solution was 1.0 mg/ml. 
2.2.3.3-Assay condition:  
The UV absorbance of both sample and standard solutions was taken at 
225 nm. 
2.2.3.4- Procedure:  
The UV absorption spectrum of azithromycin standard solution 0.001 
%w/v was scanned in the range 200-400 nm using a Lamda-2 UV/VIS 
spectrophotometer. The absorption minimum was at 212 nm and the 
maximum was at 225 nm. The maximum absorption was selected for both 
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standard and sample of azithromycin assay. The calibration curve was 
made from the fives concentrations of the azithromycin standard to check 
the system linearity. The slope, intercept, regression r2 and the calibration 
factor (CF) were calculated from the calibration curve. CF was used for 
the calculation of the potency of the azithromycin samples. 
2.3 Statistical Analysis: 
Results of the study were obtained and content percent of three 
separate samples of the same batch were statistically analyzed using 
Microsoft Excel 2003. 
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3- Results 
3.1- Results of microbiological assay 
Calculations in agar diffusion Method: (Hewitt, 1977) 
- Difference due to dose 
)}(){(
4
1
1133 susuE +−+=  
- Difference due to preparations 
)}(){(
3
1
323123 sssuuuF ++−++=  
-Log ratio of doses 
I = Log2 = 0.3010 
- Slope:-    
1
Eb =  
- Log of potency ratio )( ST    bFM =  
- Potency ratio:     
 Anti Log M =  
Content % = Anti Log M X100 
For azithromycin & clarithromycin: S1 & U1=1 µg/ml, S2 & U2 =2ug/ml, 
S3 & U3 =4 µg/ml. For erythromycin: S1 & U1=5 µg/ml, S2 & U2 =10 
µg/ml, S3 & U3 = 20 µg/ml 
Azithromycin sample-1 = Zomax ; Azithromycin sample-2 = Zocin  
Azithromycin sample31 = Azithrolyd 
Calarithromycin sample-1 = Claritop ; Calarithromycin sample-2 = Clarix 
Calarithromycin sample-3 = Clarem; Erythromycin sample-1 = 
Amithrocin ; Erythromycin sample-2 = Epomycin;  Erythromycin 
sample-3 = G.M. Erythromycin  
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Table-1: Results of microbiological assay of azithromycin sample-1 on 
day-1 
 
Item Azithromycin- sample 1 Standard Azithromycin 
Conc µg/ml 1 2 4 1 2 4 
Inhibitory 
Zone 
Diameter 
In mm 
13.8 
13.8 
13.9 
13.9 
15.9 
15.9 
15.9 
15.9 
17.7 
17.7 
17.8 
17.7 
13.9 
14 
14 
13.9 
15.8 
15.9 
15.9 
15.9 
17.9 
17.7 
17.8 
17.9 
Mean 13.85 15.9 17.73 13.95 15.9 17.83 
 
E=1.9375, F=-0.06667, 1=0.30103, b=6.436236, M'=-0.01036 
Content%=97.6 
 
Table-2: Results of microbiological assay of azithromycin sample-1 on 
day -2 
 
Item Azithromycin sample 1 Standard Azithromycin 
Conc µg/ml 1 2 4 1 2 4 
Inhibitory 
Zone 
Diameter 
In mm 
13.8 
13.9 
13.7 
13.8 
15.8 
15.7 
15.8 
15.8 
17.9 
17.8 
17.7 
18 
13.8 
14 
13.8 
13.9 
15.9 
16 
15.8 
16.1 
17.9 
18 
17.9 
17.8 
Mean 13.8 15.78 17.85 13.88 15.95 17.9 
 
E=2.01875, F=-0.1, 1=0.30103, b=6.706142, M'=-0.01491 
Content% =96.6 
 
Table-3: Results of microbiological assay of azithromycin sample-1 on 
day -3 
 
Item Azithromycin sample 1 Standard azithromycin 
Conc µg/ml 1 2 4 1 2 4 
Inhibitory 
Zone 
Diameter 
In mm 
13.6 
13.9 
13.9 
13.8 
15.8 
16 
15.9 
15.8 
17.9 
17.8 
17.8 
17.7 
13.9 
13.8 
13.9 
14 
16.1 
16 
15.9 
15.9 
18.1 
17.8 
18.2 
17.9 
Mean 13.8 15.88 17.8 13.9 15.98 18 
 
E=2.025, F=-0.13333, 1=0.30103, b=6.726904, M'=-0.01982 
Content   %   =   95.5% 
 
Average of azithromycin sample-1 = 96.6 %  
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Table-4: Results of microbiological assay of azithromycin sample-2 on 
day -1 
 
Item Azithromycin sample 2 Standard azithromycin 
Conc µg/ml 1 2 4 1 2 4 
Inhibitory 
Zone 
Diameter 
In mm 
14 
13.9 
13.9 
14 
15.8 
15.8 
15.9 
15.9 
17.9 
18 
17.8 
17.9 
14.2 
14.1 
13.8 
14 
15.8 
15.9 
15.9 
15.9 
18 
17.9 
18.2 
17.9 
Mean 13.95 15.86 17.88 14.03 15.88 18 
 
E=1.98125,  F=-0.06667, 1=0.30103, b=6.58157, M'=-0.01013 
Content   %   =   97.6% 
 
Table-5: Results of microbiological assay of azithromycin sample-2 on 
day -2 
 
Item Azithromycin sample 2 Standard azithromycin 
Conc µg/ml 1 2 4 1 2 4 
Inhibitory 
Zone 
Diameter 
In mm 
14.1 
13.9 
13.8 
14 
16 
16 
15.7 
15.9 
17.7 
17.8 
17.8 
17.7 
14.2 
13.9 
13.9 
14 
16.2 
16.1 
15.8 
15.9 
18.1 
17.7 
17.8 
18 
Mean 13.95 15.9 17.76 14 16 17.9 
 
E=1.925. F=-0.1, 1=0.30103. b=6.394712. M'=-0.01564 
Content   %   =   96.4% 
 
Table-6: Results of microbiological assay of azithromycin sample-2 on 
day -3 
 
Item Azithromycin sample 2 Standard azithromycin 
Conc µg/ml 1 2 4 1 2 4 
Inhibitory 
Zone 
Diameter 
In mm 
13.9 
13.8 
14 
14 
15.9 
16 
15.8 
15.8 
17.9 
18 
17.9 
17.8 
13.9 
13.9 
14.1 
14.1 
15.9 
16.1 
15.9 
15.8 
17.9 
18 
18.1 
17.8 
Mean 13.93 15.88 17.9 14 15.93 17.95 
 
E=1.98125.  F=-0.0583, 1=0.30103. b=6.58157. M'=-0.00886.  
Content%   =   98% 
 
Average of azithromycin sample-2 = 97.3 %  
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Table-7: Results of microbiological assay of azithromycin sample-3 on 
day -1 
 
 
E=2.05, F=-0.05833, 1=0.30103, b=6.809953, M'=-0.00857 
Content   %   =   98% 
 
Table-8: Results of microbiological assay of azithromycin sample-3 on 
day -2 
 
Item Azithromycin sample 3 Standard azithromycin 
Conc µg/ml 1 2 4 1 2 4 
Inhibitory 
Zone 
Diameter 
In mm 
13.7 
13.8 
13.7 
13.7 
15.8 
15.9 
16 
15.9 
17.9 
18.1 
17.9 
17.9 
13.8 
13.8 
14 
13.8 
16.1 
16 
16 
15.9 
18.2 
18.1 
17.8 
17.9 
Mean 13.73 15.9 17.95 13.85 16 18 
 
E=2.09375, F=-0.091671=, 0.30103, b=6.955287, M'=-0.01318 
Content   %   =   97% 
 
Table-9: Results of microbiological assay of azithromycin sample-3 on 
day -3 
 
Item Azithromycin sample 3 Standard azithromycin 
Conc µg/ml 1 2 4 1 2 4 
Inhibitory 
Zone 
Diameter 
In mm 
13.8 
13.9 
13.7 
13.8 
15.8 
15.9 
16 
15.9 
17.9 
18 
17.8 
18 
13.8 
14 
13.9 
13.9 
15.8 
15.9 
16.1 
16.1 
18 
18.1 
18.1 
17.8 
Mean 13.8 15.9 17.93 13.9 15.98 18 
 
E=2.05625, F=-0.08333, 1=0.30103, b=6.830715, M'=-0.0122 
Content   %   =   97% 
 
Average of azithromycin sample-3 = 97.3 %  
Standard Azithromycin Azithromycin- sample 3 Item 
4 2 1 4 2 1 Conc µg/ml 
18 
17.9 
18.1 
18 
15.8 
16 
16.2 
16 
14.1 
13.8 
13.8 
13.9 
17.9 
17.8 
18.1 
18 
15.9 
16.1 
16 
15.7 
13.8 
13.9 
13.9 
13.8 
Inhibitory 
Zone 
Diameter 
Mm 
18 16 13.9 17.95 15.93 13.85 Mean 
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Table-10: Results of microbiological assay of erythromycin sample-1 on 
day -1 
 
Standard Erythromycin Erythromycin- sample 1 Item 
20 10 5 20 10 5 Conc µg/ml 
20 
19.9 
19.9 
19.8 
18.2 
18.3 
18.3 
18.4 
16.5 
16.6 
16.4 
16.5 
19.8 
19.6 
19.9 
19.5 
18.2 
18.2 
18.3 
18.1 
16.4 
16.5 
16.3 
16.4 
Inhibitory 
Zone 
Diameter 
mm 
19.9 18.3 16.5 19.7 18.2 16.4 Mean 
 
E=1.7, F=-0.25, 1=0.30103, b=5.647278, M'=-0.04427 
Content   %   =   94.525% 
 
Table-11: Results of microbiological assay of erythromycin sample-1 on 
day -2 
 
Item Erythromycin sample 1 Standard Erythromycin 
Conc µg/ml 5 10 20 5 10 20 
Inhibitory 
Zone 
Diameter 
In mm 
15.8 
16 
15.7 
15.7 
17.8 
17.7 
18 
17.9 
19.9 
19.8 
19.7 
19.8 
15.9 
16.1 
16.2 
15.9 
18.1 
17.9 
17.8 
17.8 
20 
20 
19.8 
20 
Mean 15.8 17.85 19.8 16.03 17.9 19.95 
 
E=1.98125, F=-0.14167, 1=0.30103, b=6.58157, M'=-0.02152,  
Content % = 95.175% 
 
Table-12: Results of microbiological assay of erythromycin sample-1 on 
day -3 
 
Item Erythromycin sample 1 Standard Erythromycin 
Conc µg/ml 5 10 20 5 10 20 
Inhibitory 
Zone 
Diameter 
In mm 
15.9 
15.8 
15.8 
15.9 
17.8 
17.9 
17.8 
17.9 
19.8 
19.9 
19.9 
20 
15.9 
15.9 
15.9 
15.9 
18 
18 
17.8 
18 
19.8 
20 
19.9 
20.1 
Mean 15.85 17.85 19.9 15.9 17.95 19.95 
E=2.025, F=-0.06667, 1=0.30103, b=6.726904, M'=-0.00991  
Content   %   =   97.775% 
 
Average of erythromycin sample-1 = 95.8 %  
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Table-13: Results of microbiological assay of erythromycin sample-2 on 
day -1 
 
Standard Erythromycin Erythromycin- sample 2 Item 
20 10 5 20 10 5 Conc µg/ml 
19.8 
20 
19.9 
20.2 
18 
17.9 
17.9 
17.8 
16 
15.9 
15.9 
15.8 
19.9 
19.9 
19.8 
19.7 
17.8 
17.9 
17.9 
17.8 
15.8 
15.7 
15.8 
15.9 
Inhibitory 
Zone 
Diameter 
Mm 
19.98 17.9 15.9 19.83 17.85 15.8 Mean 
 
E=2.025, F=-0.1, 1=0.30103, b=6.726904, M'=-0.01487 
Content   %   =   95.875% 
 
Table-14: Results of microbiological assay of erythromycin sample-2 on 
day -2 
 
Item Erythromycin sample 2 Standard Erythromycin 
Conc µg/ml 5 10 20 5 10 20 
Inhibitory 
Zone 
Diameter 
In mm 
15.8 
15.7 
15.8 
15.9 
17.9 
17.7 
18 
17.8 
19.8 
19.7 
19.9 
19.8 
16.1 
15.8 
16 
15.9 
17.9 
17.9 
18 
17.8 
19.8 
20.1 
19.8 
19.9 
Mean 15.8 17.85 19.8 15.95 17.9 19.9 
 
E=1.9875, F=-0.1, 1=0.30103. b=6.602332, M'=-0.01515 
Content   %   =   96.65% 
 
Table-15: Results of microbiological assay of erythromycin sample-2 on 
day -3 
 
Item Erythromycin sample 2 Standard Erythromycin 
Conc µg/ml 5 10 20 5 10 20 
Inhibitory 
Zone 
Diameter 
In mm 
15.8 
15.6 
15.7 
15.7 
17.6 
17.8 
17.7 
17.9 
19.9 
19.8 
19.8 
19.7 
15.9 
15.8 
15.9 
15.8 
18 
17.9 
17.8 
17.9 
19.8 
19.9 
20 
19.9 
Mean 15.7 17.78 19.8 15.85 17.9 19.9 
 
E=2.0375, F=-0.125, 1=0.30103, b=6.768428, M'=-0.01847 
Content   %   =   95.55% 
 
Average of erythromycin sample-2 = 96 %  
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Table-16: Results of microbiological assay of erythromycin sample-3 on 
day -1 
 
Standard Erythromycin Erythromycin- sample 3 Item 
20 10 5 20 10 5 Conc µg/ml 
19.9 
20 
19.8 
20.1 
18 
17.8 
18.2 
17.9 
15.9 
16 
15.9 
15.9 
19.9 
19.9 
19.8 
19.9 
17.8 
17.9 
18 
17.9 
15.8 
15.9 
15.8 
15.7 
Inhibitory 
Zone 
Diameter 
Mm 
19.95 17.98 15.93 19.88 17.9 15.8 Mean 
 
E=2.025, F=-0.09167, 1=0.30103, b=6.726904, M'=-0.01363 
Content   %   =   96.925% 
 
Table-17: Results of microbiological assay of erythromycin sample-3 on 
day -2 
 
Item Erythromycin sample 3 Standard Erythromycin 
Conc µg/ml 5 10 20 5 10 20 
Inhibitory 
Zone 
Diameter 
In mm 
15.9 
15.8 
15.9 
15.9 
17.8 
17.8 
17.8 
17.8 
19.8 
20 
19.8 
19.8 
16 
15.9 
15.8 
15.8 
18 
17.9 
17.9 
17.9 
19.9 
20 
19.9 
19.9 
Mean 15.88 17.8 19.85 15.88 17.93 19.93 
 
E=2.00625, F=-0.06667, 1=0.30103, b=6.664618, M'=-0.01 
Content   %   =   97.75% 
 
Table-18: Results of microbiological assay of erythromycin sample-3 on 
day -3 
 
Item Erythromycin sample 3 Standard Erythromycin 
Conc µg/ml 5 10 20 5 10 20 
Inhibitory 
Zone 
Diameter 
In mm 
15.8 
15.7 
15.8 
15.9 
18 
17.9 
17.8 
17.9 
19.9 
20.2 
19.8 
19.7 
15.9 
15.8 
15.9 
16 
18.1 
17.9 
18 
18 
19.9 
20.2 
20.1 
19.8 
Mean 15.8 17.9 19.9 15.9 18 20 
 
E=2.05, F=-0.1, 1=0.30103, b=6.809953, M'=-0.01468 
Content   %   =   96.6% 
 
Average of erythromycin sample-3 = 97 %  
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Table-19: Results of microbiological assay of clarithromycin sample-1 on 
day -1 
 
Standard Clarithromycin Clarithromycin- sample 1 Item 
4 2 1 4 2 1 Conc µg/ml 
17.7 
17.7 
17.7 
17.6 
15.9 
16 
15.9 
16 
14.4 
14.4 
14.5 
14.5 
17.6 
17.7 
17.6 
17.4 
15.7 
15.8 
15.8 
15.9 
14.3 
14.4 
14.4 
14.4 
Inhibitory 
Zone 
Diameter 
Mm 
17.68 15.95 14.45 17.58 15.8 14.38 Mean 
 
E=1.60625, F=-0.10833, 1=0.30103, b=5.335847, M'=-0.0203 
Content  %= 95.4 
 
Table-20: Results of microbiological assay of clarithromycin sample-1 on 
day -2 
 
Item Clarithromycin sample 1 Standard Clarithromycin 
Conc µg/ml 1 2 4 1 2 4 
Inhibitory 
Zone 
Diameter 
In mm 
14.3 
14.2 
14.5 
14.3 
15.8 
15.9 
15.9 
16.2 
17.6 
17.7 
17.6 
17.6 
14.4 
14.3 
14.4 
14.5 
16.1 
16 
16.1 
16.2 
17.6 
17.7 
17.9 
17.8 
Mean 14.33 15.95 17.63 14.4 16.1 17.75 
 
E=1.6625, F=-0.11667, 1=0.30103, b=5.522705, M'=-0.02112 
Content   %   =   95.3% 
 
Table-21: Results of microbiological assay of clarithromycin sample-1 on 
day -3 
 
Item Clarithromycin sample 1 Standard Clarithromycin 
Conc µg/ml 1 2 4 1 2 4 
Inhibitory 
Zone 
Diameter 
In mm 
14.1 
14.4 
14.3 
14.3 
15.8 
15.9 
15.9 
15.9 
17.5 
17.6 
17.4 
17.5 
14.2 
14.5 
14.3 
14.3 
15.9 
16.1 
15.9 
16 
17.6 
17.5 
17.6 
17.6 
Mean 14.28 15.88 17.55 14.33 15.98 17.58 
 
E=1.63125, F=-0.05833, 1= 0.30103, b=5.418895, M'=-0.01076 
Content   %   =   97% 
 
Average of clarithromycin sample-1 = 95.9 %  
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Table-22: Results of microbiological assay of clarithromycin sample-2 on 
day -1 
 
Standard Clarithromycin Clarithromycin- sample 2 Item 
4 2 1 4 2 1 Conc µg/ml 
18 
18.1 
18.2 
18.1 
16.1 
16.1 
16.2 
16.1 
14.4 
14.3 
14.3 
14.5 
18.1 
17.9 
18.1 
17.8 
15.9 
16.1 
16.2 
15.9 
14.4 
14.2 
14.1 
14.3 
Inhibitory 
Zone 
Diameter 
Mm 
18.1 16.13 14.38 17.98 16.03 14.25 Mean 
 
E=1.8625,  F=-0.11667, 1=0.30103,  b=6.187091,  M'=-0.01886 
Content   %   =   95.8% 
 
Table-23: Results of microbiological assay of clarithromycin sample-2 on 
day -2 
 
Item Clarithromycin sample 2 Standard Clarithromycin 
Conc µg/ml 1 2 4 1 2 4 
Inhibitory 
Zone 
Diameter 
In mm 
14.4 
14.3 
14.3 
14.2 
16 
16.1 
16.3 
15.9 
18 
17.9 
18 
17.9 
14.4 
14.3 
14.5 
14.2 
16.3 
16.3 
16.2 
16 
18 
17.9 
18.1 
18 
Mean 14.3 16.1 17.95 14.35 16.2 18 
 
E=1.825, F=-0.066671=0.30103, b=6.062519, M'=-0.011 
Content   %   =   97.45% 
 
Table-24: Results of microbiological assay of clarithromycin sample-2 on 
day -3 
 
Item Clarithromycin sample 2 Standard Clarithromycin 
Conc µg/ml 1 2 4 1 2 4 
Inhibitory 
Zone 
Diameter 
In mm 
14.3 
14.2 
14.3 
14.3 
16 
16 
16.1 
16.1 
18 
17.9 
17.9 
17.9 
14.4 
14.2 
14.4 
14.3 
16.1 
16.1 
16.3 
16.2 
18.1 
17.9 
17.9 
18 
Mean 14.28 16.05 17.93 14.33 16.18 17.98 
 
E=1.825, F=-0.075, 1=0.30103, b=6.062519, M'=-0.01237 
Content   %   =   97.2% 
 
Average of clarithromycin sample-2 = 96.8 %  
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Table-25: Results of microbiological assay of clarithromycin sample-3 on 
day -1 
 
Standard Clarithromycin Clarithromycin- sample 3 Item 
4 2 1 4 2 1 Conc µg/ml 
18.1 
18.5 
18.2 
18.0 
16.5 
16.3 
16.3 
16.5 
14.4 
14.5 
14.6 
14.6 
18.1 
18.4 
18.1 
18.0 
16.2 
16.3 
16.2 
16.4 
14.4 
14.4 
14.6 
14.5 
Inhibitory 
Zone 
Diameter 
Mm 
18.2 16.4 14.53 18.15 16.28 14.48 Mean 
 
E=1.8375, F=-0.075, 1=0.30103, b=6.104043, M'=-0.01229 
Content   %   =   97.2% 
 
Table-26: Results of microbiological assay of clarithromycin sample-3 on 
day -2 
 
Item Clarithromycin sample 3 Standard Clarithromycin 
Conc µg/ml 1 2 4 1 2 4 
Inhibitory 
Zone 
Diameter 
In mm 
14.3 
14.4 
14.4 
14.2 
16.3 
16.2 
16.4 
16.3 
18.4 
18.1 
18.2 
18.0 
14.4 
14.5 
14.6 
14.4 
16.5 
16.4 
16.5 
16.4 
18.5 
18.2 
18.3 
18.2 
Mean 14.33 16.3 18.18 14.48 16.45 18.3 
 
E=1.91875, F=- 0.14167, 1=0.30103, b=6.37395, M'=-0.02223 
Content   %   =   95% 
 
Table-27: Results of microbiological assay of clarithromycin sample-3 on 
day -3 
 
Item Clarithromycin sample 3 Standard Clarithromycin 
Conc µg/ml 1 2 4 1 2 4 
Inhibitory 
Zone 
Diameter 
In mm 
14.3 
14.5 
14.1 
14.3 
16.3 
16.2 
16.2 
16.3 
18.1 
18.1 
18.2 
18.1 
14.4 
14.3 
14.4 
14.5 
16.3 
16.4 
16.2 
16.5 
18.3 
18.2 
18.3 
18.1 
Mean 14.3 16.25 18.13 14.4 16.35 18.23 
 
E=1.9125, F=-0.1, 1=0.30103, b=6.353187, M'=-0.01574 
Content   %   =   96.475% 
 
Average of clarithromycin sample-3 = 96.2 %  
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Figure 4: Microbiological assay of azithromycin 
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Figure 5 : Microbiological assay of azithromycin 
sample-1 (day-2) 
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Figure 6 : microbiological assay of azithromycin 
sample-1 (day-3)
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Figure 7: Microbiological assay of azithromycin 
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Figure 8: Microbiological assay of azithromycin 
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Figure 9: Microbiological assay of azithromycin
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Figure 10: Microbiological assay of azithromycin 
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Figure 11: Microbiological assay of azithromycin 
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Figure 12: Microbiological assay of azithromycin 
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Figure 13: Microbiological assay of erythromycin 
sample-1 (day-1)
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Figure 14:  Microbiological assay of erythromycin 
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Figure 15 : Microbiological assay of erythromycin 
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Figure 16: Microbiological assay of erythromycin 
sample-2 (day-1)
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Figure 17 : Microbiological assay of erythromycin 
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Figure 18 : Microbiological assay of erythromycin 
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Figure 19 : Microbiological assay of erythromycin 
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Figure 20: Microbiological assay of  erythromycin 
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Figure 21 : Microbiological assay of erythromycin 
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Figure 22: Microbiological assay of clarithromycin 
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Figure 23:  Microbiological assay of clarithromycin 
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Figure 24: Microbiological assay of clarithromycin 
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Figure 25 : Microbiological assay of Clarithromycin 
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Figure 26: Microbiological assay of carithromycin 
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Figure 27: Microbiological assay of clarithromycin 
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Figure 28: Microbiological assay of clarithromycin 
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Figure 29: Microbiological assay of clarithromycin 
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Figure 30: Microbiological assay of clarithromycin 
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3.2: Results of HPLC assay 
 
Table-28: Results of HPLC-assay (Clarithromycin) 
 
Drug Concentration Peak area Potency Average 
Standard-1 
Standard-2 
Standard-3 
Standard-4 
Standard-5 
0.125 mg/ml 
0.25 mg/ml 
0.5 mg/ml 
1.0 mg/ml 
2.0 mg/ml 
62.72203 
125.8822 
233.4381 
501.3858 
901.2133 
 
  
Sample-1 
Experiment-1 
Experiment-2 
Experiment-3 
 
0.5 mg/ml 
0.5 mg/ml 
0.5 mg/ml 
 
221.766 
223.634 
227.602 
 
95% 
95.80% 
97.50% 
 
 
 
96.1 % 
Sample-2 
Experiment-1 
Experiment-2 
Experiment-3 
 
0.5 mg/ml 
0.5 mg/ml 
0.5 mg/ml 
 
224.801 
223.167 
226.435 
 
96.30% 
95.60% 
97% 
 
 
 
96.3 % 
Sample-3 
Experiment-1 
Experiment-2 
Experiment-3 
 
0.5 mg/ml 
0.5 mg/ml 
0.5 mg/ml 
 
227.602 
224.101 
225.735 
 
97.50% 
96% 
96.70% 
 
 
 
96.7 % 
 
From the calibration curve: Regression factor, slope, Intercept and the 
calibration factor were found to be 0.996556, 449.7829, 16.34657 and 
0.002223 respectively 
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Figure 31 : Calbriation curve of Clarithromycin 
                          (HPLC) method
y = 461.67x
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3.3. Results of spectrophotometric assay 
Table-29: Results of spectrophotometric assay (Azithromycin) 
 
Drug Concentration Absorbance Potency Average 
Standard-1 
Standard-2 
Standard-3 
Standard-4 
Standard-5 
0.25 mg/ml 
0.5 mg/ml 
1.0 mg/ml 
2.0 mg/ml 
4.0 mg/ml 
0.156 
0.285 
0.585 
1.211 
2.389 
  
Sample-1 
Experiment-1 
Experiment-2 
Experiment-3 
 
1.0 mg/ml 
1.0 mg/ml 
1.0 mg/ml 
 
0.562 
0.545 
0.552 
 
96% 
94% 
94.30% 
 
 
 
94.8 % 
Sample-2 
Experiment-1 
Experiment-2 
Experiment-3 
 
1.0 mg/ml 
1.0 mg/ml 
1.0 mg/ml 
 
0.549 
0.560 
0.563 
 
93.80% 
95.80% 
96.30% 
 
 
 
95.3 % 
Sample-3 
Experiment-1 
Experiment-2 
Experiment-3 
 
1.0 mg/ml 
1.0 mg/ml 
1.0 mg/ml 
 
0.565 
0.559 
0.567 
 
96.60% 
95.60% 
97% 
 
 
 
96.4 % 
 
From the calibration curve: Regression factor, slope, Intercept and the 
calibration factor were found to be 0.999818, 0.599376, -0.00383 and 
1.6684 respectively. 
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Figure 32 : Calibration curve of Azithromycin 
(spectrophometric) method
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3.4-Comparison of microbiological assay to chemical assay  
Paired student two-sided t’ test at α level of 0.05 (p ≥ 0.05) 
decision was based on value of calculated tstat.  
Table-30: Azithromycin sample-1 
Content % 
Biological assay spectrophotometric assay 
96.6 96 
98.8 94 
97.6 94.3 
t = 0.142222041 
No significant difference at p < 0.05 
 
Table-31: Azithromycin sample-2 
Content % 
Biological assay spectrophotometric assay 
96.5 93.8 
97.7 95.8 
96.7 96.3 
t = 0.1319758 
No significant difference at p < 0.05 
 
Table-32: Azithromycin sample-3 
 Content   % 
Biological assay spectrophotometric assay 
97.6 96.6 
98.9 95.6 
98.9 97 
 t =  0.0937404 
No significant difference at p < 0.05 
 96
Table-33: Clarithromycin sample-1 
Content  % 
Biological assay HPLC assay 
97.2 95 
94.6 95.8 
95.8 97.5 
t=  0.389904 
No significant difference at p < 0.05 
 
Table-34: Clarithromycin sample-2  
Content % 
Biological assay HPLC assay 
98.7 96.3 
96.4 95.6 
96.6 97 
t =  0.3688312 
No significant difference at p < 0.05 
 
Table-35: Clarithromycin sample-3  
Content % 
Biological assay HPLC assay 
97.7 97.5 
96.3 96 
97.4 96.7 
t =  0.120117 
There is no significant difference at p < 0.05 
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Table-36: Variations of microbiological assays within the day 
      Coefficient of variation < 10% 
 
Drug Content % Mean 
(M) 
Standard 
deviation 
(SD) 
Coefficient 
Variation%= 
SD/M*100% 
azith-1 day-1 96.6,98.8, 97.6, 97.7 97.675% 0.899537 0.9 % 
azith-1 day-2 98.9,93.2,  96.6,  97.7 96.6% 2.453569 2.5 % 
azith-1 day-3 91.7,101.2,95.6,  94.2 95.675% 4.02109 4.2 % 
azith-2 day-1  96.5,97.7, 96.7,  99.3 97.55% 1.279323 1.3 % 
azith-2 day-2 91.7, 99.7, 97.7, 96.5 96.4% 3.4 3.5 % 
azith-2 day-3 98,  97.8,  97.4,   98.8 98% 0.588784 0.6 % 
azith-3 day-1 96.6, 98.9, 98.9,  97.6 98% 1.116542 1 % 
azith-3 day-2 92.8, 98.9, 97.7,  98.9 97,075% 2.905598 3 % 
azith-3 day-3 98.9, 97.8, 93.5,  98.9 97.275% 2.569533 2.6 % 
Clar-1 day-1 94.6,97.2,95.8,94.1 95.425% 1.381726 1.4 % 
Clar-1 day-2 94.5, 97.4, 94.6, 94.6 95.275% 1.417451 1.5 % 
Clar-1 day-3 96,  97,  97.2,  97.8 97% 0.748331 0.8 % 
Clar-2 day-1 98.7, 96.4, 96.6, 91.5 95.8% 3.04959 3.2 % 
Clar-2 day-2 97.2, 97.5, 97.5, 97.6 97.45% 0.173205 0.2 % 
Clar-2 day-3 96.3,98.8, 96.2, 97.5 97.2% 1.219289 1.3 % 
Clar-3 day-1 96.3, 97.7, 97,4, 97.4 97.2% 0.616441 6.3 % 
Clar-3 day-2 95.6, 95.1, 95.2, 94.1 95% 0.637704 6.7 % 
Clar-3 day-3 96.5, 98.8, 95.5, 95.1 96.475% 1.658061 1.7 % 
Ery-1 day-1 96, 93, 98.7, 90.4 94.525% 3.603124 3.8 % 
Ery-1 day-2 94.5, 94.2, 95.3, 96.7 95% 1.117661 1.2 % 
Ery-1 day-3 97.7, 96.7, 98.9, 97.8 97.775% 0.899537 0.9 % 
Ery-2 day-1 96.6, 96.7, 94.6, 95.6 95.875% 0.984463 1 % 
Ery-2 day-2 96.5, 92.5, 98.8, 98.8 96.65% 2.971532 3 % 
Ery-2 day-3 95.5, 95.6, 94.5, 96.6 95.55% 0.858293 0.9 % 
Ery-3 day-1 96.6, 98.8, 96.6, 95.7 96.925% 1.320038 1.4 % 
Ery-3 day-2 95.4, 97.8, 98.9, 98.9 97.75% 1.650253 1.7 % 
Ery-3 day-3 97.7, 98.9, 93.4, 96.4 96.6% 2.365023 2.4 % 
   
No significant variation of microbiological assays within the day at 
coefficient of variation < 10%. 
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Table-37: Variations of microbiological assays betweens days 
Coefficient of variation < 10% 
 
Content% 
Drug 
Day-1 Day-2 Day-3 
Mean 
(M) 
Standard 
Deviation 
(SD) 
Coefficient 
Variation%
= SD/M* 
100% 
Azithromycin 
sample-1 
97.675 96.6 95.675 96.65 1.000937 1 % 
Azithromycin 
samle-2 
97.55 96.4 98 97.317 0.825126 0.8 % 
Azithromycin 
sample-3 
98 97,075 97.275 97.45 0.486698 0.5 % 
Clarithromycin 
Sample-1 
95.425 95.275 97 95.9 0.955576 1 % 
Clarithromycin 
Sample-2 
95.8 97.45 97.2 96.817 0.889288 9.2 % 
Clarithromycin 
Sample-3 
97.2 95 96.475 96.225 1.121104 1.2 % 
Erythromycin 
Sample-1 
94.525 95 97.775 95.767 1.755408 1.8 % 
Erythromycin 
Sample-2 
95.875 96.65 95.55 96 0.565133 0.6 
Erythromycin 
Sample-3 
96.925 97.75 96.6 97 0.592839 0.6 % 
 
No significant variation of microbiological assays between days at 
coefficient of variation < 10%. 
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4- Discussion 
Macrolide antibiotics are widely used in humans and food-
producing animals. Because of extensive worldwide use clinically for 
human and veterinary, macrolide antibiotics are expected to be widely 
distributed in biological and environmental samples. Antibiotics released 
into the environment are of concern because they have potential to 
accelerate development of antibiotic resistance in bacteria from food 
producing animals and resistance gene transfer to humans. (Potera C. 
2001)  
Microorganism in Foods and environments contaminated with 
antibiotics could function as reservoirs of antibiotics resistance genes. 
(Assaf et al 1999) 
Therefore, it is necessary to develop an accurate and robust detection 
method for determination of the macrolide antibiotics in pharmaceutical 
dosage forms. This method may be used for monitoring residues in food 
and environmental exposure to macrolide antibiotics.  
Macrolide antibiotics are assayed in official monographs either by 
microbiological assay or HPLC coupled to UV or electrochemical 
detectors. (USP-28, BP-2004) 
Erythromycin stearate tablets are assayed microbiologically in both 
monographs while the raw material is assayed by HPLC-methods. 
There is no specific method for determination of the new 
macrolide antibiotics azithromycin and clarithromycin in their 
pharmaceutical dosage forms in BP up to 2004 edition, while the pure 
form of the antibiotic is assayed by HPLC-methods. (BP-2004) 
Azithromycin capsules method of assay is HPLC coupled to 
electrochemical detector, while clarithromycin tablets method of assay is 
HPLC coupled to UV detector. (USP-28) 
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Biological assays have been introduced to determine the 
concentration of a single type of macrolide using erythromycin-sensitive 
strains as indicators. (Riedel et al. 1992, and Assaf et al. 1999) Biological 
assay method is routinely used for the determination of the efficacy and 
the activity of antibiotics towards test microorganisms. The biological 
activities of antibiotics are semi-quantitatively measured, typically using 
two fold serial dilutions of drug concentrations in microtiter plates. 
Although it is convenient for the estimation of effective drug 
concentrations by logical analysis, it is difficult to distinguish activities 
of individual drugs in mixtures showing synergistic effects. (Eguchi et al 
2004)  
Azithromycin has been analyzed in biological samples by various 
methods including microbiological assay, (Turcinov et al 1998) and 
HPLC methods, (Taninaka et al 2000). 
However, there is noticeable shortage of methods described in the 
literature for its determination in pharmaceutical dosage forms. 
Chromatographic methods developed for azithromycin quantification 
requires expensive equipment not available in many laboratories. 
(Gandhi et al 2000) Fluorimetric methods reported require a prior 
derivatization of the drug. (Pakinas. Y. Khashaba  2002) 
In the present study microbiological assay was conducted to solve 
the problems mentioned above especially in developing countries where 
the selected detectors used for chromatographic assay are not available. 
The method is developed for quantitative determination of azithromycin 
in its pharmaceutical dosage forms. The method was found to be accurate 
and all commercially available drugs assayed were within the range of 
official monographs (90-110% USP-28). Linear (r2   around 0.999 for all 
drugs assayed), precise and high reproducibility was achieved, the 
coefficient of variation (CV) of three separate samples solution of the 
studied azithromycin of the same batch gave a CV less than 10% for all 
 101
samples used (table 36 &37). This level of precision is suitable for the 
routine quality control analysis of pharmaceutical dosage forms.  
Although the biological assays have a high variability, the results 
obtained demonstrate that, the proposed method is very useful for the 
determination of azithromycin in pharmaceutical dosage forms and hence 
evaluation of the potency of the antibiotics.  
The activity or potency of antimicrobial agents may be demonstrated 
under suitable conditions by their inhibitory effect on microorganisms. 
(USP-28) 
However the microbiological assay is not free from certain 
disadvantages, eg time consumption and lack of sensitivity towards other 
antibiotics. For this reason the current study developed a fast and simple 
and economic method for determination of azithromycin in its 
pharmaceutical dosage forms. Spectrophotometric with UV detection 
method was used for analysis of azithromycin capsules. Azithromycin in 
its pure form was scanned in the spectrophotometer and the absorbance 
was found to be 212nm minimum and 225nm maximum. The maximum 
wave length 225 was selected for the analysis of azithromycin capsules. 
The method was compared to biological assay (table 30, 31, 32); and 
found to be easy, fast, simple and economic in both time and reagents. It 
gives the result as the biological assay in minuets. The only solvent used 
was methanol. The calibration curve of the absorbance against 
concentration gave a linear line and the r2 = 0.9998. 
Microbiological assay was compared to the spectrophotometric 
assay using the student t-test. The calculated values of probability at p< 
0.05 listed in tables (30, 31, 32) indicate that there is no significant 
difference between the two methods of assay.  
Clarithromycin assayed officially by HPLC coupled to UV 
detector. (USP-28) However there are many methods reported in the 
literature for clarithromycin determination in pharmaceutical dosage 
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forms and biological samples. Chromatographic techniques including 
TLC, paper chromatography, GS, capillary zone electrophoresis and 
HPLC-methods in pharmaceutical formulation and biological samples 
using UV detector and electrochemical detector were evaluated. (Kanfer 
et al 1998) Clarithromycin was also assayed microbiologically. 
(Bernabelu et al 1999) 
No studies were reported in the literature for comparing the 
microbiological assay and HPLC-methods for tablets from the same 
batch of clarithromycin. The present study analyzed clarithromycin by 
the two methods and it has been found that the microbiological assay was 
linear (r2 were around 0.999), accurate, precise and having high 
reproducibility, according to the coefficient of variation (CV) of three 
separate solution samples of clarithromycin of the same batch. It gave a 
CV less than 10% for all samples used (table 36&37). This level of 
precision is suitable for the routine quality control analysis of 
pharmaceutical dosage forms. The present study also compared these two 
methods of analysis using the student t-test. It has been found that the 
microbiological assay of clarithromycin gave the same results as the 
official HPLC-method and according to the calculated values of 
probability at p< 0.05 listed in tables (33, 34, 35) there is no significant 
difference between the two methods of assay. Microbiological assay of 
clarithromycin has shown that the clarithromycin has potent in vitro 
activity against Bacillus pumilus, and this action is added to the 
advantages of this method which shows the activity as well as the 
potency of the antibiotic. The comparison of the two methods shows that 
the microbiological assay is a good alternative method. It is particularly 
useful in areas with limited laboratory facilities. This method is also 
useful for determining pattern of resistance in areas where antibiotics are 
irrationally used.  
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The fermentation process that produces commercial grade 
erythromycin is not entirely selective. It results in the production of small 
quantities of erythromycin-B (EB), C (EC), D (ED), E (EE) and F (EF), 
in addition to erythromycin-A, which is the major component and 
constitute about 95% of the mixture. However EB, EC and EE are the 
most important impurities found in commercial samples of erythromycin. 
In addition to the related substances, the metabolite demethyl 
erythromycin, and acidic and basic degradation products are also present 
in small quantities in commercial samples of erythromycin. These 
include erythromycin enol ether, anhydroerythromycin, erythrolosamine, 
pseudoerythromycin A hemiketal, pseudoerythromycin A enol ether and 
dehydroerythromycin. Other related substances such as erythromycin A 
N-oxide, erythromycin oxime and erythromycylamine also exist and are  
structurally very similar, differing by only hydrogen, hydroxyl and/or 
methoxy groups. (Omura S. 1984) and (Omura S., and Nakagama 1975) 
Initial attempts to analyze erythromycin involved the use of TLC to 
separate erythromycin mixture. (Anderson  1964)  
After that there are many studies conducted for separation and 
analysis of erythromycin mixture, gas liquid chromatography has been 
used for quantitative analysis and separation of erythromycin in mixtures 
containing related compounds and degradation products using flam-
ionization detection. (Tsugi 1971)  
However, HPLC remains the most extensively used 
chromatographic method for the analysis of erythromycin and related 
substances. Reverse-phase HPLC method with mobile phase consisting 
of an organic modifier and ammonium acetate buffer and elevated 
temperature (70 C°) to shorten the analysis time and increased the 
resolution using UV detection wavelength of 215nm was used for 
analysis and separation of erythromycin and related compounds in a 
solution. (Tsnji 1978)  
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There are also many other methods and studies reported in 
literature for analysis of erythromycin and related compounds in 
solutions or biological samples e.g. stability indicating assay for 
erythromycin in serum and urine using amperometric detection. (Stubbs 
et al 1987) And HPLC with amperometric detection for separation of 
erythromycin in plasma and urine. (Critean et al 1987)  
From the literature review it has been found that there is a 
noticeable shortage in the studies for analysis of erythromycin tablets by 
HPLC. Erythromycin tablets are assayed in official monograph by 
microbiological assay [USP-28 and BP-2004]. 
The objective of this study is to compare the results of 
microbiological assay to HPLC- assay. But unfortunately, it has been 
found that it’s very difficult to analyze erythromycin tablets by HPLC- 
methods. This may be due to interference between erythromycin and 
related compound with one or more of the excipients of the tablets 
formulation. It has been found that the peak of erythromycin sample 
(stereate tablets) is bigger than the peak of erythromycin working 
standard which proved to be the same commercial sample used for tablets 
formulation standardized with reference standard of WHO specifications. 
Erythromycin working standard contains the same related compounds of 
erythromycin samples for tablets formulation. For this reason it may be 
concluded that the only source of interference of erythromycin peak with 
the unknown compound peak is the excipients of the tablets formulation. 
And this is may be the reason for keeping the microbiological assay as 
the official Pharmacopoeial method of erythromycin assay.  
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Conclusion and Recommendation 
Conclusion 
 -  Azithromycin & clarithromycin can be assayed 
microbiologically. 
-  Microbiological assay and chemical assay gave the same 
results. 
-  Microbiological assay is the best method of analysis of 
erythromycin. 
Recommendation: 
Future studies should tackle the problem of interference of tablet 
excipients in HPLC assay of erythromycin. 
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